Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity

ABSTRACT

A method for treating diseases in which tryptase inhibitors may be of thereapeutic value, which comprises the administration of a thereapeutic amount of a compound of the formula The invention also comprises novel compounds of the formula (I). Exemplary is 2-[2-(4-amidinophenyl)ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(pyridin-3-yl-methyl)-N-methyl-amide-hydrochloride.

RELATED APPLICATIONS

Benefit of U.S. Provisional Application Serial No. 60/153,423, filed on Sep. 10, 1999, is hereby claimed.

FIELD OF THE INVENTION

The invention relates to the use of certain aminocarbonyl-substituted benzimidazole derivatives for the treatment of diseases in which inhibition of tryptase is of therapeutic value, certain novel aminocarbonyl-substituted benzimidazole derivatives having tryptase-inhibitory activity, methods for preparing their preparation and pharmaceutical compositions containing such compounds.

BACKGROUND OF THE INVENTION

Benzimidazole derivatives are known from the prior art as active substances with valuable pharmaceutical properties. Thus, International Patent Application WO 98/37075 discloses, in addition to other bicyclic heterocycles, benzimidazoles, which can be used to good effect, on the basis of their thrombin-inhibiting activity, to prevent and treat venous and arterial thrombotic diseases.

In contrast to the use of benzimidazole derivatives described hereinbefore and known from the prior art, the aim of the present invention is to prepare new tryptase inhibitors which can be used, by virtue of their tryptase-inhibiting properties, to prevent and treat inflammatory and/or allergic diseases.

DETAILED DESCRIPTION OF THE INVENTION

It has been found, surprisingly, that aminocarbonyl-substituted benzimidazole derivatives of general formula (I)

 

wherein the groups R¹, R², R³ and R⁴ may have the meanings given hereinafter, have a tryptase-inhibiting effect and may be used according to the invention for the prevention and treatment of diseases in which tryptase inhibitors may be of therapeutic value.

Thus, a first aspect of the invention is a method for treating diseases in which tryptase inhibitors may be of thereapeutic value, which method comprises the administration, to a host in need of such treatment, of a thereapeutic amount of a compound of the formula (I)

 

wherein:

R¹ denotes C₁-C₁₀-alkyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkoxy, phenoxy, hydroxyphenoxy, C₁-C₄-alkoxy-phenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO-benzyl, or

phenyl-C₁-C₄-alkyl, wherein the phenyl ring may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a single bond or via a C₁-C₄-alkylene bridge, which may contain one, two or three heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, optionally by C₁-C₄-alkyl substituted phenyl or optionally by C₁-C₄-alkyl substituted benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂;

R³ and R⁴ which may be identical or different, denote hydrogen, C₁-C₆-alkyl, which may be mono- or disubstituted by one or more of the groups COOH, COO—C₁-C₄-alkyl, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may optionally be mono-, di- or tri-substituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH, COO—C₁-C₄-alkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked directly or via a C₁-C₄-alkylene bridge, which may contain one, two, three or four heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or

C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

R³ and R⁴ together with the nitrogen atom form a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group, which may contain one or two further heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and which may optionally be substituted by one or more of the groups C₁-C₄-alkyl, C₅-C₆-cycloalkyl, benzyl, which may optionally be substituted by C₁-C₄-alkyl, pyridyl or phenyl, optionally substituted by C₁-C₄-alkyl, C₁-C₄-alkoxy or hydroxy,

or a tautomer or pharmacologically acceptable acid addition salt thereof.

The phrase “a host in need of such treatment” as used herein means a patient, whether animal or human, which or who suffers from a disease which is treatable by the inhibition of tryptase.

The above-described thereapeutic method may be used to treat inflammatory and/or allergic diseases. Even more particularly, the above-described method may be used for the treatment of bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, allergic otitis, allergic gastro-intestinal disorders, Crohn's disease, ulcerative colitis, anaphylactic shock, septic shock, shock lung (ARDS) and arthritis.

The compounds of formula (I) as described above for may also be used, in accordance with the invention, for the treatment of fibroses such as lung fibrosis, fibrosing alveolitis and scarring, collagenoses such as lupus erythematodes and sclerodermia as well as arteriosclerosis, psoriasis and neoplasm.

Some of the above-described compounds of the formula (I) are known and others are novel. These novel compounds of formula (I) constitute a second aspect of the invention.

The novel compounds provided by the invention are those of the formula (I)

 

wherein

R denotes C₁-C₁₀-alkyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkoxy, phenoxy-, C₁-C₄-alkoxy-phenoxy, hydroxyphenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO-benzyl, or

phenyl-C₁-C₄-alkyl, wherein the phenyl ring may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a single bond or via a C₁-C₄-alkylene bridge, which may contain one, two or three heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and

may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, optionally by C₁-C₄-alkyl substituted phenyl or optionally by C₁-C₄-alkyl substituted benzyl, or to which a benzene ring may optionally be fused via two adjacent carbon atoms;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂;

R³ denotes C₁-C₆-alkyl, which is mono- or disubstituted by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or benzyl, wherein the phenyl ring is mono- or disubstituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

phenyl-C₂-C₄-alkyl, wherein the C₂-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may optionally be mono- or di-substituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which may contain one, two or three heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl;

R⁴ denotes hydrogen, C₁-C₆-alkyl, which may be mono- or disubstituted by one or more of the groups COOH, COO—C₁-C₄-alkyl or C₃-C₆-cycloalkyl, or

phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl and wherein the phenyl ring may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which contains a heteroatom selected from the group comprising oxygen, nitrogen or sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or

R³ and R⁴ together with the nitrogen atom form a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group, which contains one or two further heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and may optionally be substituted by one or more of the groups C₁-C₄-alkyl; benzyl, which is optionally C₁-C₄-alkyl-substituted, C_(5-C) ₆-cycloalkyl, pyridyl or phenyl, which optionally bears a group selected from the group comprising C₁-C₄-alkyl, C₁-C₄-alkoxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

Preferred are compounds of general formula (I), wherein

R¹ denotes unsubstituted C₁-C₁₀-alkyl, or

may be mono- or disubstituted by C₁-C₄-alkoxy, phenoxy, C₁-C₄-alkoxy-phenoxy, hydroxyphenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or NH—CO-benzyl substituted C₁-C₄-alkyl, or

phenyl-C₁-C₃-alkyl, wherein the phenyl ring may optionally be mono- or disubstituted by C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₃-alkylene bridge, which may contain one or two heteroatoms selected from the group comprising oxygen, nitrogen or sulphur and may optionally be mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl- or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂;

R³ denotes C₁-C₆-alkyl, which is mono- or disubstituted by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

benzyl, wherein the phenyl ring is substituted directly or via a C₁-C₄-alkylene bridge by one of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

phenyl-C₂-C₄-alkyl, wherein the C₂-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may be substituted directly or via a C₁-C₄-alkylene bridge by one of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which may contain one or two heteroatoms selected from the group comprising oxygen or nitrogen and may optionally be mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl or benzyl;

R⁴ hydrogen, C₁-C₄-alkyl, which may be substituted by one of the groups COOH, COO—C₁-C₄-alkyl or C₃-C₆-cycloalkyl, or

phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl and wherein the phenyl ring may optionally be mono- or disubstituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono- or disubstituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which contains a heteroatom selected from the group comprising oxygen, nitrogen or sulphur and which may optionally be mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or

R³ and R⁴ together with the nitrogen atom form a 6- or 7-membered, saturated or unsaturated heterocyclic group, which contains one or two further heteroatoms selected from the group comprising oxygen or nitrogen and which may optionally be substituted by one or more of the groups methyl, ethyl, propyl, benzyl, cyclopentyl, cyclohexyl, pyridyl or phenyl, which optionally carries a group selected from the group comprising methyl, methoxy, ethoxy, propyloxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

More preferred are compounds of general formula (I), wherein

R¹ denotes unsubstituted C₁-C₁₀-alkyl, or by C₁-C₄-alkoxy, phenoxy, C₁-C₄-alkoxy-phenoxy, hydroxyphenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO-NH—(C₁-C₄-alkyl) or —NH—CO-benzyl substituted C₁-C₄-alkyl, or

phenyl-C₁-C₃-alkyl, wherein the phenyl ring may optionally be mono- or disubstituted by C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or

a heterocyclic group linked via a C₁-C₃-alkylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl or benzyl, selected from the group comprising pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, pyrimidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, triazole, furan, tetrahydrofuran, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, thiophene, dihydrothiophene, thiolan, dithiolan, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, benzodioxole, benzimidazole, benzothiophene, benzofuran or indole;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂;

R³ denotes C₁-C₃-alkyl, which is substituted by —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

benzyl, wherein the phenyl ring is substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

phenyl-C₂-C₃-alkyl, wherein the C₂-C₃-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₃-alkyl and wherein the phenyl ring may be substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —C(═NH)NH₂ or —NH—C(═NH)NH₂, or

a heterocyclic group linked via a C₁-C₃-alkylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl or benzyl, selected from the group comprising pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, pyrimidine, piperazine morpholine, diazepan, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, furan, tetrahydrofuran, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, oxazole or isoxazole;

R⁴ denotes hydrogen, C₁-C₄-alkyl, which may be substituted by one of the groups COOH, COO—C₁-C₃-alkyl or C₃-C₆-cycloalkyl, or

phenyl-C₁-C₃-alkyl, wherein the C₁-C₃-alkylene bridge may optionally be substituted by phenyl and wherein the phenyl ring may optionally be substituted by C₁-C₃-alkyl, C₁-C₃-alkoxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₃-alkyl, or

C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono- or disubstituted by one or more of the groups C₁-C₃-alkyl, C₁-C₃-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₃-alkyl, or

a heterocyclic group linked via a C₁-C₃-alkylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl- or benzyl, selected from the group comprising pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, pyrimidine, piperazine morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, triazole, furan, tetrahydrofuran, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, thiophene, dihydrothiophene, thiolan, dithiolan, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, benzodioxole, benzimidazole, benzothiophene, benzofuran or indole; or

R³ and R⁴ together with the nitrogen atom form a 6- or 7-membered, saturated heterocyclic group, which contains one or two further nitrogen heteroatoms and which may optionally be substituted by one or more of the groups methyl, ethyl, propyl, benzyl, cyclopentyl, cyclohexyl, pyridyl or phenyl, which optionally carries a group selected from the group comprising methyl, methoxy, ethoxy, propyloxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

Still more preferred are compounds of general formula (I), wherein

R¹ denotes methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl, or

a methyl, ethyl or propyl group which is substituted by methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, methoxyphenoxy, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO-methyl, —CO—NH₂, —CO—NH-methyl or —NH—CO-benzyl, or

benzyl, which is mono- or disubstituted by methyl, ethyl, propyl, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or

phenylethyl, which is mono- or disubstituted by methyl, ethyl, propyl, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or

a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl or benzyl, selected from the group comprising pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, furan, tetrahydrofuran, thiophene, benzodioxole or benzimidazole;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂;

R³ denotes a methyl, ethyl or propyl group which is substituted by —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl), —NH-benzyl or —C(═NH)NH₂, or

benzyl, which is substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl) or —C(═NH)NH₂, or

phenyl-C₂-C₃-alkyl, wherein the C₂-C₃-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₃-alkyl and

wherein the phenyl ring may be substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂, or

a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by methyl, ethyl, propyl, phenyl or benzyl, selected from the group comprising pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, diazepan, furan, tetrahydrofuran, thiophene, benzodioxole or benzimidazoles;

R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group which may be substituted by one of the groups COOH, COOMe, COOEt, cyclopropyl, cyclopentyl or cyclohexyl, or

benzyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenylethyl, phenylpropyl, diphenylpropyl;

cyclopropyl, cyclopentyl, cyclohexyl, cyclooctyl, naphthyl or phenyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or

a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by methyl, ethyl, propyl, phenyl or benzyl, selected from the group comprising pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, furan, tetrahydrofuran, thiophene, quinoline, isoquinoline, benzodioxole or benzimidazole; or

R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring which may optionally be substituted by one of the groups methyl, ethyl, propyl, cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries a group selected from the group comprising methyl, methoxy ethoxy, propyloxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

Especially preferred according to the invention are compounds of general formula (I), wherein

R¹ denotes methyl, ethyl, propyl, pentyl or n-decyl,

 or

a methyl, ethyl- or propyl group which is substituted by methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl or methoxyphenoxy, or

benzyl, which is mono- or disubstituted by methyl, CF₃, COOH, COOMe or COOEt,

 or

a tetrahydrofuran linked via a methylene bridge;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂;

R³ denotes an ethyl or propyl group which is substituted by —NH₂, —NHMe, —NMe₂, —NHEt, —NEt₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂, or

benzyl which is substituted by one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO—Me or —C(═NH)NH₂, or

phenylethyl, wherein the ethylene bridge may be substituted by COOH, COOMe or COOEt and wherein the phenyl ring is optionally substituted by one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)N₂, or

phenylpropyl, diphenylpropyl or pyridylmethyl;

R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group, which may be substituted by one of the groups COOH, COOMe, COOEt, cyclopropyl, cyclopentyl or cyclohexyl, or

benzyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenyl-ethyl, phenylpropyl, diphenylpropyl, or

cyclopentyl, cyclohexyl, cyclooctyl, naphthyl or phenyl, which may optionally be substituted by methyl, ethyl, methoxy, ethoxy, phenyloxy or CF₃, or

a pyridine or quinoline linked via a methylene bridge, or

R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring, which may optionally be substituted by one of the groups cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries one of the groups selected from the group comprising methyl, methoxy, ethoxy, propyloxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

More especially preferred according to the invention are compounds of general formula (I), wherein

R¹ denotes methyl, ethyl, propyl, pentyl, phenylethyl, phenylpropyl, cyclopropylmethyl, tetrahydrofuranylmethyl or benzyl, which is mono- or disubstituted by CF₃, COOH, COOMe or COOEt;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂, preferably —C(═NH)NH₂;

R³ denotes an ethyl or propyl group which is substituted by —NH₂, —NHMe, —NMe₂, —NHEt, —NEt₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂,

or benzyl substituted by one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)NH₂,

or phenylethyl, wherein the ethylene bridge is substituted by COOH, COOMe or COOEt and wherein the phenyl ring carries one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)NH₂, or phenylpropyl, diphenylpropyl or pyridylmethyl;

R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group which may be substituted by one of the groups COOH, COOMe, COOEt or cyclohexyl, or

phenyl, which may optionally be substituted by methyl, ethyl, methoxy, ethoxy, phenyloxy or CF₃, or

benzyl, phenylethyl, phenylpropyl, diphenylpropyl, cyclohexyl, cyclooctyl or naphthyl, or

a pyridine or quinoline linked via a methylene bridge, or

R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring, which may optionally be substituted by one of the groups cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries a group selected from the group comprising methyl, methoxy, ethoxy, propyloxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

Still more especially preferred are compounds of general formula (I), wherein

R¹ denotes methyl;

R² denotes —C(═NH)NH₂ or —CH₂—NH₂, preferably —C(═NH)NH₂;

R³ denotes ethyl, substituted by —NH₂, —NMe₂, —NHphenyl, —NHbenzyl, —N(benzyl)₂, pyrrolidine, piperidine, diazepan or —C(═NH)NH₂, benzyl substituted by one of the groups —CH₂—NH₂, —NMe₂ or —C(═NH)NH₂, phenylethyl, wherein the ethylene bridge is substituted by COOH, COOMe or COOEt and wherein the phenyl ring carries one of the groups —CH₂—NH—CO-Me or —C(═NH)NH₂, diphenylpropyl or pyridylmethyl;

R⁴ denotes hydrogen or a methyl or ethyl group which may optionally be substituted by one of the groups COOH or COOEt; propyl, butyl or phenyl, which may optionally be substituted by methyl, ethyl, methoxy, ethoxy, phenyloxy or CF₃; benzyl, phenylethyl, phenylpropyl, diphenylpropyl, cyclohexyl, cyclooctyl, naphthyl, pyridylmethyl or quinolinylmethyl or

R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring substituted by one of the groups benzyl, cyclopentyl, cyclohexyl or phenyl, which optionally carries a group selected from the group comprising methyl, ethoxy, propyloxy or hydroxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

Even more preferred are compounds of general formula (I), wherein

R¹ denotes methyl;

R² denotes —C(═NH)NH₂;

R³ denotes ethyl, substituted by —NH₂, —NHphenyl, —NHbenzyl, —N(benzyl)₂, pyrrolidine, piperidine, diazepan or —C(═NH)NH₂; benzyl substituted by —C(═NH)NH₂, or diphenylpropyl;

R⁴ denotes hydrogen, methyl, propyl, butyl, benzyl or phenyl, which may optionally be substituted by ethyl or phenyloxy; phenylethyl, cyclohexyl or cyclooctyl, or

R³ and R⁴ together with the nitrogen atom form a piperazine ring which is substituted by a group selected from the group comprising cyclopentyl, cyclohexyl, phenyl, methylphenyl, ethoxyphenyl or propoxyphenyl, or a diazepan ring substituted by methylphenyl,

optionally in the form of their tautomers, their racemates, their enantiomers, their diastereomers and mixtures thereof and optionally the pharmacologically acceptable acid addition salts thereof.

Penultimately preferred are those compounds of general formula (I) according to the invention wherein

R¹ denotes methyl;

R² denotes —C(═NH)NH₂;

R³ denotes ethyl, substituted by —NH₂, —NHbenzyl, —N(benzyl)₂, pyrrolidine, piperidine, diazepan or —C(═NH)NH₂, benzyl substituted by —C(═NH)NH₂, or diphenylpropyl;

R⁴ denotes hydrogen, methyl, butyl or phenyl, which may optionally be substituted by ethyl or phenyloxy; phenylethyl, cyclohexyl or cyclooctyl, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereomers and mixtures thereof and optionally the pharmacologically acceptable acid addition salts thereof.

Ultimately preferred in accordance with the invention are the following specific compounds of the formula (I):

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonsäure-N-(2-amidinoethyl)-N-(2-phenylethyl)-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-[2-N′,N′-dibenzylamino)ethyl]-N-phenyl-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-amidinoethyl)-N-(3-phenoxy-phenyl)-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-amidinoethyl)-N-phenyl-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-amidinoethyl)-N-cyclooctyl-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-amidinoethyl)-N-(3-ethyl-phenyl)-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N-(2-(N′-benzylamino)-ethyl)-N-cyclohexyl-amide];

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N-(2-amino-ethyl)-N-cyclohexyl-amide];

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(3,3-diphenylpropyl)-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-amidino-benzyl)-N-methyl-amide;

2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-amidinoethyl)-N-iso-butyl-amide;

2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(cyclohexyl)-piperazide]; and, 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methyl-phenyl)-diazepide].

Apart from the abovementioned compounds of general formula (I) the present invention is also directed to compounds which are only converted into the therapeutically effective compounds of general formula (I) by the body after being taken by the patient, on the basis of a functionality which can be cleaved in vivo. Such compounds are known as prodrugs. According to another aspect the invention therefore relates to prodrugs of general formula (II)

 

wherein

R¹ and R⁴ may be as hereinbefore defined and

R³ may have the meanings given hereinbefore or denotes C₁-C₄-alkyl, which is substituted by a group selected from the group comprising —C(═NOH)NH₂, —C(═NCOO—C₁-C₄-alkyl)NH₂ or —C(═NCOO—C₁-C₄-alkyl-phenyl)NH₂;

R⁵ may denote hydroxy, —COO—C₁-C₈-alkyl or —COO—C₁-C₄-alkyl-phenyl, whilst in the abovementioned group the phenyl ring may be substituted by C₁-C₄-alkyl or C₁-C₄-alkoxy,

and tautomers and pharmacologically acceptable acid addition salts thereof.

Preferred are prodrugs of general formula (II), wherein

R¹, R³ and R⁴ may be as hereinbefore defined and

R⁵ may denote hydroxy, methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, benzyloxycarbonyl, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereomers and mixtures thereof and optionally the pharmacologically acceptable acid addition salts thereof.

In another aspect the present invention relates to compounds of general formula (III)

 

wherein the groups R¹, R³ and R⁴ may be as hereinbefore defined. The compounds of general formula (III) are valuable intermediate products for preparing the aminocarbonyl-substituted benzimidazole derivatives of general formula (I) according to the invention and the prodrugs of general formula (II) according to the invention.

The term alkyl groups (including those which are part of other groups) denotes branched and unbranched alkyl groups with 1 to 10 carbon atoms, preferably 1-6, most preferably 1-4 carbon atoms, such as, for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl. Unless otherwise stated, the above terms propyl, butyl, pentyl, hexyl, heptyl and octyl also include all the possible isomeric forms. For example, the term propyl also includes the two isomeric groups n-propyl and iso-propyl, the term butyl includes n-butyl, iso-butyl, sec. butyl and tert.-butyl, the term pentyl includes iso-pentyl, neopentyl, etc. In some cases common abbreviations are also used to denote the abovementioned alkyl groups, such as Me for methyl, Et for ethyl etc.

Examples of cycloalkyl groups with 3-8 carbon atoms include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Fluorine, chlorine, bromine or iodine is generally referred to as halogen.

Examples of N-linked cyclic groups of general formula NR³R⁴ include: pyrrole, pyrroline, pyrrolidine, 2-methylpyrrolidine, 3-methylpyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine or diazepan, which may be substituted as specified in the definitions.

Examples of 5-, 6- or 7-membered, saturated or unsaturated heterocycles which may contain nitrogen, oxygen or sulphur as heteroatoms, include, unless otherwise stated in the definitions, furan, tetrahydrofuran, tetrahydrofuranon, γ-butyrolactone, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, thiophene, dihydrothiophene, thiolan, dithiolan, pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, tetrazole, pyridine, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxazole, isoxazole, oxazine, thiazole, isothiazole, thiadiazole, oxadiazole and pyrazolidine, wherein the heterocyclic group may be substituted as stated in the definitions.

“═O” denotes an oxygen atom linked via a double bond.

Aminocarbonyl-substituted benzimidazole derivatives of formula (I) and the prodrugs of general formula (II) may be synthesised using the methods of synthesis known from the prior art. In this respect, attention is drawn to International Patent Application WO 98/37075 mentioned earlier, the contents of which are hereby referred to.

One possible method of obtaining the compounds according to the invention with the aid of and using conventional chemical methods of synthesis is diagrammatically shown hereinafter (Diagram 1).

 

In a first step (step i, Diagram 1) 4-amino-3-nitrobenzoic acid derivatives are synthesised, starting from 4-halo-3-nitro-benzoic acid derivatives, by aminolysis with suitably substituted primary amines. The reaction is carried out in suitable organic solvents such as dimethyl sulphoxide, N,N-dimethylformamide, N-methylpyrrolidone or optionally in water at ambient temperature or in a temperature range from 30-80° C., preferably 40-50° C. The aminobenzoic acid compounds thus obtained are converted by standard conventional methods into the corresponding alkylesters, preferably into the corresponding methylesters or ethylesters (step ii, Diagram 1). The reduction of the nitro group to the alkyl diaminobenzoates is preferably carried out by catalytic hydrogenation according to step iii (Diagram 1). The preferred catalyst is palladium. Palladium on charcoal (5%) is particularly preferred as the catalyst. By reacting the diaminobenzoates thus obtained with p-cyanophenylpropionic acid in the presence of dehydrating reagents, the benzimidazole heterocycle is formed according to step v (Diagram 1). The reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane. Suitable dehydrating agents include, for example, isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, phosphorus oxychloride, thionylchloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, ethyl 1,2-dihydro-2-ethoxy-quinoline-1-carboxylate (EEDQ), i-propylester 1,2-dihydro-2-i-propyloxy-quinolin-1-carboxylate (IIDQ), N,N′-dicyclohexylcarbodiimide, N,N′-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N′-dicyclohexylcarbodiimide/1-hydroxy-benztriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole, N,N′-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride. In some cases it may prove useful to add a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine. The reaction is normally carried out at temperatures between 0 and 150° C., preferably at temperatures between 0 and 110° C.

The benzimidazole derivatives of general formula (III) which may be prepared according to step v (Diagram 1) are either obtainable directly from the abovementioned benzimidazole carboxylates or are obtained via the corresponding carboxylic acids or carboxylic acid halides.

If the carboxylic acid esters obtained in step iv (Diagram 1) are saponified under standard conditions (protic organic solvent such as methanol, ethanol or isopropanol, for example. optionally in the presence of water and in the presence of bases such as hydroxides or carbonates of alkali and alkaline earth metals), this leads to the corresponding free carboxylic acids. Usually, this saponification is carried out at temperatures between 0-40° C., preferably at 10-30° C. If desired, however, the synthesis may also be carried out at elevated temperature (>50° C. to reflux temperature).

The preferred solvent according to the invention is a methanol-water mixture. The base used is preferably sodium hydroxide. The reaction of the resulting acid with the amines H—NR³R⁴ to obtain the compounds of general formula (III) is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane or in the corresponding amine H—NR³R⁴, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionylchloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N′-dicyclohexylcarbodiimide, N,N′-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N′-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole, N,N′-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine, appropriately at temperatures of between 0 and 150° C., preferably at temperatures of between 0 and 100° C.,

The synthesis of the compounds of general formula (III) starting from the carboxylates obtained in Diagram 1 (step iv) or from the corresponding carboxylic acid chlorides is carried out either in the corresponding amine H—NR³R⁴ as solvent, or with the amine H—NR³R⁴ in the presence of a solvent such as methylene chloride, ether or ethyl acetate and preferably in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine at temperatures of between 0 and 150° C., preferably at temperatures of between 40 and 100° C.

A compound of general formula (I) is obtained for example by treating a compound of general formula (III, Diagram 1, step vi) with a corresponding alcohol such as methanol, ethanol, n-propanol, isopropanol or benzylalcohol optionally mixed with another organic solvent such as for example chloroform, nitrobenzene or toluene in the presence of an acid such as hydrochloric acid or by reacting a corresponding amide with a trialkyloxonium-salt such as triethyloxonium tetrafluoroborate in a solvent such as methylene chloride, tetrahydrofuran or dioxane at temperatures of between −10 and 50° C., but preferably at 0-20° C. Alternatively, the compounds of general formula (I) may be obtained by reacting a compound of general formula (III) (Diagram 1, step vi) with sulphur nucleophiles such as e.g. hydrogen sulphide, ammonium or sodium sulphide, sodium hydrogen sulphide, carbon disulphide, thioacetamide or bistrimethylsilylthioether optionally in the presence of bases such as triethylamine, ammonia, sodium hydride or sodium alkoxide in solvents such as methanol, ethanol, water, tetrahydrofuran, pyridine, dimethylformamide or 1,3-dimethyl-imidazolidin-2-one at 20-100° C., and subsequently treating with a suitable methylating agent such as e.g. methyl iodide or dimethyl sulphate in a solvent such as acetonitrile or acetone at temperatures of between −10 and 50° C., but preferably at 0-20° C. and then treating with ammonia, ammonium carbonate or ammonium chloride in a suitable alcohol, such as for example methanol, ethanol, isopropanol etc. at temperatures between −10 and 50° C., but preferably at 0-20° C.

Moreover, the compounds of general formula (I) according to the invention may be obtained by treating a compound of general formula (III) with lithium hexamethyldisilazide in a suitable organic solvent such as e.g. tetrahydrofuran at temperatures of between −20 and 50° C., but preferably at 0-20° C. and then hydrolysing with dilute hydrochloric acid at 0-5° C.

Another alternative method of obtaining compounds of general formula (I) is by treating a compound of general formula (III) with ammonium chloride and trimethylaluminium in a suitable organic solvent such as e.g. toluene at temperatures of between 20 and 150° C., but preferably at 110° C.

A compound of general formula (II) is obtained for example by treating a compound of general formula (III, Diagram 1, step vii) with hydroxylamine in the presence of carbonates or alkoxides of the alkali or alkaline earth metals in solvents such as methanol, ethanol, n-propanol or isopropanol optionally mixed with dioxane or tetrahydrofuran. The alkoxides may be prepared from the respective alkali metals or metal hydrides and the corresponding alcohol. The reaction is preferably carried out at 20-100° C., most preferably at the boiling temperature of the solvent used.

Compounds of general formula (II) may alternatively be prepared by treating a compound of general formula (III, Diagram 1, step vii) with a corresponding alcohol such as methanol, ethanol, n-propanol, isopropanol or benzylalcohol in the presence of an acid such as hydrochloric acid or by reacting a corresponding amide with a trialkyloxonium-salt such as triethyloxonium-tetrafluoroborate in a solvent such as methylene chloride, tetrahydrofuran or dioxane at temperatures of between −10 and 50° C., but preferably at 0-20° C. and subsequently treating with hydroxylamine in the presence of bases in a suitable alcohol, such as methanol, ethanol, isopropanol etc. at temperatures of between −10 and 50° C., but preferably at 0-20° C.

A compound of general formula (I) may be obtained for example by treating a compound of general formula (II, Diagram 1, step viii) with hydrogen in the presence of hydrogenation catalysts such as Raney nickel or rhodium/aluminium oxide in water or methanol, optionally with the addition of acids such as hydrochloric acid or methanesulphonic acid or by treating with hydrogen in the presence of palladium/charcoal in acetic acid/acetic anhydride at 20-50° C. and 1-5 bar hydrogen pressure, preferably at ambient temperature and normal pressure.

Acyl- or alkoxycarbonyl prodrugs of the compound of general formula (I) are obtained by reacting the compounds of general formula (I) with the corresponding acid chlorides in the presence of bases such as e.g. triethylamine, N-methylmorpholine, diethylisopropylamine or DBU in a suitable solvent such as methylene chloride, chloroform, tetrahydrofuran, acetonitrile, dimethylformamide or dimethyl sulphoxide.

Alternatively to the method described above the compounds according to the invention may also be obtained on a polymeric carrier by means of a solid phase synthesis. The method of production by solid phase synthesis, as shown by way of example in Diagram 2 in a manner which must not be regarded as restricting the core of the invention, is of particular interest for those compounds according to the invention wherein the group R³ is terminally amino-substituted.

 

In a first step (Diagram 2, step i) a resin-bound diamine is reacted. The resins which may be used are usually trityl, 2-chlorotrityl, 4-methoxytrityl resins with polymer matrices of crosslinked polystyrene or Tentagel or Synphase™ crowns. In order to carry out the synthesis step according to Diagram 2 (step i) the same procedure is used as hereinbefore, according to the invention. 2-4 equivalents of the diamine, based on the resin charge, are dissolved in an organic solvent selected from the group comprising dichloromethane, tetrahydrofuran, 1,2-dichloroethane or dimethylformamide. The solution is added to the trityl resin and stirred for 2-16 h at ambient temperature. Then the resin is filtered off and washed several times with dry pyridine or a mixture of dichloromethane/diisopropylamine and dichloromethane or dry diethylether. The resin is dried in vacuo until a constant weight is obtained.

In a second step (Diagram 2, step ii) the diamine coupled to the resin is reacted in a reductive amination with the aldehydes R⁴—CHO, wherein R⁴ may have the meanings given hereinbefore. The following procedure is used for this. 2-10 Equivalents of the aldehyde R⁴—CHO, dissolved in tetramethyl orthoformate/dichloromethane or dichloromethane or dichloromethane/dimethylformamide or dimethylformamide or 1,2-dichloromethane, are added to diamine-charged resin, suspended in tetramethyl orthoformate or dichloromethane, dimethylformamide, 1,2-dichloromethane, 1-methyl-2-pyrrolidone (each with added tetramethyl orthoformate) and shaken for 2-12 h at 0-30° C. Then the resin is washed and mixed with a solution of sodium triacetoxyborohydride or sodium cyanoborohydride in dichloromethane or DMF or 1,2-dichloromethane at 0-30° C. and agitated for 2-24 h. Alternatively the aldehyde and the reducing agent may be added directly to the resin.

In the third step the amine coupled to the resin is reacted with 4-chloro-3-nitrobenzoylchloride in an acylating reaction (Diagram 2, step iii). The following procedure is used for this. The resin is suspended in dichloromethane or dimethylformamide or 1,2-dichloromethane or 1-methyl-2-pyrrolidone or tetrahydrofuran with the addition of a base such as triethylamine or diisopropylethylamine or pyridine and combined at ambient temperature with a solution of 4-chloro-3-nitro-benzoylchlorid in dichloromethane or 1,2-dichloroethane or 1-methyl-2-pyrrolidone or dimethylformamide or tetrahydrofuran and shaken for 1-12 h at ambient temperature. Then the mixture is filtered and washed with various solvents. Alternatively to the method shown by way of example in Diagram 2, it is possible to use 4-fluoro-3-nitro-benzoylchloride, for example, instead of the 4-chloro-3-nitro-benzoylchloride.

There is then a Nucleophilic Substitution at the benzoic acid amide coupled to the resin by the primary amines R¹—NH₂.(Diagram 2, step iv). The following procedure is used for this, according to the invention. The resin, suspended in diisopropylethylamine solution or in 1-methyl-2-pyrrolidone or dimethylformamide (20% v/v), is combined with a solution of an amine R¹—NH₂ in 1-methyl-2-pyrrolidone or dimethylformamide and heated for 2-24 h in a temperature range from 50-110° C. After cooling to ambient temperature the resin is filtered off and washed with various solvents.

The reduction of the nitro group leads according to step v (Diagram 2) to the diaminobenzoic acid amides coupled to the resin. The following procedure is used for this, according to the invention. The resin is suspended in dimethylformamide or 1-methyl-2-pyrrolidone, combined with 5-50 equivalents of 1.0 M SnCl₂ solution in dimethylformamide or in 1-methyl-2-pyrrolidone and shaken for 12-48 h at ambient temperature. Then the resin is filtered off and washed intensively with various solvents. Alternatively to the reduction with the abovementioned SnCl₂ solutions, the reaction may also be carried out for example with sodium borohydride/Cu(acac)₂ (cat.) or Na₂S₂O₄ in protic organic solvents such as alcohols, preferably in ethanol.

By reacting with the aldehydes R²—C₆H₄—CH₂CH₂—CHO according to step vi (Diagram 2) the resin-coupled benzimidazole heterocycles are obtained by oxidative cyclisation. The following procedure is used for this, according to the invention. The resin is suspended in tetrahydrofuran or dioxane or 1-methyl-2-pyrrolidone, combined with a solution of an aldehyde R²—C₆H₄—CH₂CH₂—CHO in THF or dioxane or 1-methyl-2-pyrrolidone and shaken for 12-48 h at ambient temperature in oxygen from the air. Then the resin is filtered off and washed.

After the cleaving of the resin, the compounds of general formula (I) according to the invention can thus be obtained (Diagram 2, step vii). The following procedure is used according to the invention for the cleaving. The resin is shaken with trifluoroacetic acid (10-70% v/v) in dichloromethane for 1 h at ambient temperature and suction filtered. Then the resin remaining is once again combined with trifluoroacetic acid (10-70% v/v) in dichloromethane, suction filtered, and the combined filtrates are evaporated down in vacuo. After the resin residue has been treated with a mixture of dichloromethane/methanol it is filtered off after 1 h shaking at ambient temperature.

The filtrates and the residues obtained are combined and evaporated to dryness in vacuo.

Procedures by way of example for preparing the compounds according to the invention will be described in more detail hereinafter. The Examples which follow serve solely as a detailed illustration without restricting the subject matter of the invention.

EXAMPLE 1 2-[2-(4-Amidinophenyl)ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(pyridin-3-yl-methyl)-N-methyl-amide-hydrochloride

 

a) 4-Methylamino-3-nitrobenzoic Acid:

20 g (100 mmol) of 4-chloro-3-nitro-benzoic acid are taken up in 80 mL 40% aqueous methylamine solution, stirred for 15 h at ambient temperature and 1.5 h at 40-50° C.

After cooling the mixture is acidified with acetic acid. The crystals formed are filtered off, washed with cold water and dried. Yield: 18.2 g (93%); melting point: >220° C.

b) Methyl 4-Methylamino-3-nitro-benzoate:

9.8 g (50 mmol) of 4-methylamino-3-nitro-benzoic acid are combined with K₂CO₃ (14 g) in 50 mL DMF. To this suspension 5 mL of dimethyl sulphate are added dropwise within 10 min. with stirring. The temperature rises to about 35° C. The mixture is stirred for 15 minutes and then heated to 60° C. for 0.5 h. After cooling the mixture is diluted with water, the solid precipitated is filtered off, washed with water and dried. Yield: 9.8 g (93%); melting point: 138-140° C.;

c) Methyl 3-Amino-4-methylamino-benzoate:

71 g of methyl 4-methylamino-3-nitro-benzoate (338 mmol) are hydrogenated in 1.4 L of methanol and 67 mL of concentrated aqueous hydrochloric acid in the presence of 15 g Pd/C (5%) at 2-5 bar at ambient temperature. After the catalyst has been filtered off and the solvent distilled off in vacuo the residue is taken up in 200 mL water, covered with ethyl acetate and made alkaline with 50% aqueous potassium carbonate solution. The produce is extracted into the organic phase which is washed with water again and finally dried over sodium sulphate. After the majority of the solvent has been distilled off in vacuo the residue is combined with diethylether and cooled. The crystals formed are filtered off.

Yield: 54 g (81%); melting point: 215-220° C. (decomposition);

d) Methyl 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylate:

7.5 g (42 mmol) of methyl 3-amino-4-methylamino-benzoate and 7.3 g (42 mmol) of p-cyano-phenylpropionic acid are taken up in 50 mL of phosphorus oxychloride and refluxed for 2 h. After cooling the excess phosphorus oxychloride is decomposed with ice water. Ethyl acetate is poured over and the mixture is made alkaline with potassium carbonate with stirring. The organic phase is separated off, washed with water and dried. After most of the solvent has been distilled off in vacuo the mixture is cooled. The crystals precipitated are filtered off and washed with cold ethyl acetate or diethylether. Yield: 8.5 g

(63%); melting point: 148-150° C.; mass: calc.: [319], found: [M+H]⁺ 320, [M+Na]⁺ 342, [2M+H]⁺ 639; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.18 (7H, m, aryl-H); 3.86 (3H, s, OCH₃); 3.75 (3H, s, aryl-N—CH₃); 3.26 (4H, s, aryl-CH₂—CH₂—).

e) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid:

5.0 g (15.7 mmol) of methyl 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylate are taken up in 50 mL methanol, combined with 20 mL of aqueous sodium hydroxide solution (1N) and refluxed for 0.5 h. The mixture is combined with 20 mL of aqueous hydrochloric acid (1N) and diluted with water. The crystals precipitated are filtered off, washed with water, acetone and ether. The crude product obtained is recrystallised from dimethylformamide.

Yield: 4.5 g (94%); melting point: >220° C.;

f) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(pyridin-3-yl-methyl)-N-methyl-amide:

1.2 g of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid (4 mmol), 3-(methylaminomethyl)-pyridine (0.49 g, 4 mmol) and 0,7 mL of N-methylmorpholine are taken up in 20 mL dimethylformamide. Then 1.6 g of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (=TBTU; 5 mmol) are added and stirred for 16 h at RT. After dilution with 75 mL of ethyl acetate the mixture is washed with saturated, aqueous sodium hydrogen carbonate solution and washed with water and dried over sodium sulphate. After most of the solvent has been distilled off the precipitate formed is filtered off and washed with ether. Yield: 1.2 g (73%); melting point: 150-153° C.;

g) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(pyridin-3-yl-methyl)-N-methyl-amide-hydrochloride:

1.1 g (2.7 mmol) of 2-[2-(4-Cyanophenyl)-ethyl]- -methyl-benzimidazol-5-yl-carboxylic acid-[N-(pyridin-3-yl-methyl)-N-methyl-amide are taken up in 25 mL of a cooled ethanolic HCl solution saturated at 0° C. It is stirred until the educt has dissolved completely and the temperature is maintained at 0-5° C. for about 12 h. The ethanol is distilled off at a maximum of 40° C. and the residue is taken up in 30 mL of an ethanolic ammonia solution saturated at 0° C. It is stirred for 1 h at ambient temperature and 2 h at 40-50° C., combined with a further 10 mL of the abovementioned ammonia solution, refluxed for 1 h and left to stand for 12 h at ambient temperature. The inorganic salts precipitated are filtered off, the filtrate is evaporated down to half and diluted with 50 mL of acetone. The crystals precipitated are filtered off and washed with acetone.

Yield: 1.0 g (80%); melting point: >220° C. mass: calc.: [426], found: [M+H]⁺ 427, [M+2H]²⁺ 214; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.64-7.26 (11H, m, aryl-/pyridyl-H); 4.79 (2H, s, N—CH₂—); 3.72 (3H, s, aryl—N—CH₃); 3.30 (4H, s, aryl-CH₂—CH₂—); 3.02 (3H, s, CO—N—CH₃).

EXAMPLE 2 2-[2-(4-Amidinophenyl)ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-(N,N-dibenzylamino)ethyl]-N-cyclohexyl-amide-dihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid Chloride:

7.0 g (23 mmol) of 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid (obtainable according to Example 1, step e), 2 drops of dimethylformamide and 70 mL of thionylchloride are refluxed for 3 h. The excess thionylchloride is distilled off and the solid residue remaining is taken up in acetonitrile/diethylether and filtered. The solid filtered off is washed with diethylether.

Yield: 7.8 g (94%);

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-(N′,N′-dibenzylamino)-ethyl]-N-cyclohexyl-amide:

4.0 g (11 mmol) of 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride are added in batches to 3.2 g (10 mmol) of N′,N′-dibenzyl-N-cyclohexyl-ethylenediamine and 3 mL N-methylmorpholine in 75 mL of ethyl acetate with stirring at RT. The mixture is stirred for 0.5 h at 40-50° C., cooled, poured onto water and extracted with ethyl acetate. The organic phase is washed with dilute aqueous sodium hydroxide solution and with water, dried over sodium sulphate and most of the solvent is distilled off in vacuo. The residue is diluted with diethylether and cooled. The crystals precipitated are filtered off and washed with diethylether.

Yield: 5.7 g (94%); melting point: 124-126° C.;

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-[2-(N′,N′-dibenzylamino)-ethyl]-N-cyclohexyl-amide-dihydrochloride:

The reaction was carried out starting from 9.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-[2-(N′,N′-dibenzylamino)-ethyl]-N-cyclohexyl-amide analogously to Example 1, step g. The product is obtained by crystallisation from acetone with some water. Yield: 67%; melting point: 140-148° C. (dihydrochloride, contains water of crystallisation); mass: calc.: [626], found: [M+H]⁺ 627, [M+2H]²⁺ 314; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.35, 9.10 (4H, 2s, C(═NH₂ ⁺)NH₂); 7.86-7.01 (17H, m, aryl-H); 3.66, 2.60 (4H, 2 m, N—CH₂—CH₂—N); 3.75 (3H, s, aryl-N—CH₃); 3.62 (1H, m, N-cyclohexyl-H); 3.26 (4H, s, aryl-CH₂—CH₂—); 1.71-054 (10H, m, cyclohexyl).

EXAMPLE 3 2-[2-(4-Amidinophenyl)-ethyl]1l-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-(N,N-dimethylamino)-ethyl]-N-methyl-amide-dihydrochlonide

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-(N,N-dimethylamino)-ethyl]-N-methyl-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with N,N,N′-trimethylethylenediamine. The product is crystallised from ethyl acetate/diethyl ether.

Yield: 62%; melting point: 130-132° C.;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-(N,N-dimethylamino)-ethyl]-N-methyl-amide-dihydrochloride:

The reaction was carried out starting from 6 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-[2-(N,N-dimethylamino)-ethyl]-N-methyl-amide analogously to Example 1, step g. The product is obtained by crystallisation from acetone and is washed with cold ethanol/diethylether.

Yield: 71%; melting point: >220° C. (dihydrochloride); mass: calc.: [406], found: [M+H]⁺ 407, [2M+H]⁺ 814; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=10.70 (1H, s, H+); 9.38, 9.21 (4H, 2 s, —C(═NH₂ ⁺)NH₂); 7.89-7.25 (7H, m, aryl-H); 3.80, 3.33 (4H, 2 m, N—CH₂—CH₂—) (3H, s, aryl-N—CH3); 3.26 (4H, m, aryl-CH₂—CH₂—); 2.99 (3H, s, CO—N—CH₃); 2.80 (6H, s, N—(CH₃)₂).

EXAMPLE 4 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidino-benzyl)-N-methyl-amide-trihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-cyanobenzyl)-N-methyl-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 10 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with N-(4-cyanobenzyl)-N-methylamine. Yield: 81%; melting point: 138-140° C.;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidino-benzyl)-N-methyl-amide-trihydrochloride:

The reaction was carried out starting from 7 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-cyanobenzyl)-N-methyl-amide analogously to Example 1, step g. The product is obtained by crystallisation from acetone and is washed with cold ethanol/diethylether.

Yield: 68%; melting point: >220° C. (trihydrochloride); mass: calc.: [467], found: [M+H]⁺ 468; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=10.2 (1H, broad, H⁺); 9.52, 9.47, 9.36, 9.31 (8H, 4 s, 2—C(═NH₂ ⁺)NH₂); 8.00-7.20 (11H, m, aryl-H); 4.77 (2H, s, N—CH₂—); 3.78 (3H, s, aryl-N—CH₃); 3.26 (4H, s, aryl-CH₂—CH₂—); 2.95 (3H, s, CO—N—CH₃).

EXAMPLE 5 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidino-benzyl)-N-ethoxycarbonylmethyl-amide-dihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-cyanobenzyl)-N-ethoxycarbonylmethyl-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 9 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with N-(4-cyanobenzyl)-N-ethoxycarbonylmethyl-amine. The crude product is purified by chromatography on silica gel (dichloromethane:ethanol=25:1). Yield: 62%; yellow oil;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidino-benzyl)-N-ethoxycarbonylmethyl-amide-dihydrochloride:

The reaction was carried out starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-cyanobenzyl)-N-ethoxycarbonylmethyl-amide analogously to Example 1, step g. The product is obtained by chromatography on silica gel (dichloromethane:ethanol=4:1).

Yield: 89%; solid foam; mass: calc.: [539], found: [M+H]⁺ 540; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.63, 9.54, 9.44, 9.38 (8H, s, 2 C(═NH₂ ⁺)NH₂); 8.13-7.30 (11H, m, aryl-H); 4.83 (2H, s, N—CH₂-aryl); 4.19 (2H, s N—CH₂—C═O); 3.81 (3H, s, aryl-N-—H₃); 3.89 (2H, q, J=7.2 Hz, —O—CH₂—); 3.30 (4H, s, aryl-CH₂—CH₂—); 1.07 (3H, t, J=7.2 Hz, —O—CH₂-CH₃).

EXAMPLE 6 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-dimethylaminobenzyl)-N-methyl-amide-hydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-dimethylaminobenzyl)-N-methyl-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 2.3 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with N-(4-dimethylaminobenzyl)-N-methyl-amine. The crude product is purified by chromatography on silica gel (dichloromethane:ethanol=98:2). Yield: 77%;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-dimethylaminobenzyl)-N-methyl-amide-hydrochloride:

The reaction was carried out starting from 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-dimethylaminobenzyl)-N-methyl-amide analogously to Example 1, step g. The product is obtained by chromatography on silica gel (dichloromethane:methanol=9:1). Yield: 62%; solid foam; mass: calc.: [468], found: [M+H]⁺ 469; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.33, 9.12 (4H, 2 s, C(═NH₂ ⁺)NH₂); 7.89-6.66 (11H, m, aryl-H); 4.49 (2H, s, N—CH₂—); 3.75 (3H, s, aryl-N—CH₃); 3.27 (4H, s, aryl-CH₂—CH₂—); 2.88 (6H, s, N—(CH₃)₂); 2.85 (3H, s, CO—N—CH₃);.

EXAMPLE 7 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-methyl-amide-dihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-methyl-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with N-(2-cyanoethyl)-N-methyl-amine. Yield: 61%; melting point: 150-152° C.;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-methyl-amide-dihydrochloride:

The reaction was carried out starting from 2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-methyl-amide analogously to Example 1, step g. The product is obtained by chromatography on silica gel (dichloromethane:methanol=7:3). Yield: 67%; solid foam; mass: calc.: [405], found: [M+H]⁺ 406; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=7.70 (7H, m, aryl-H); 3.88, 2.81 (4H, m, N—CH₂—CH₂—); 3.71 (3H, s, aryl-N—CH₃); 3.29 (4H, s, aryl-CH₂—CH₂—); 3.08 (3H, s, CO—N—CH₃).

EXAMPLE 8 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(quinolin-3-yl-methyl)-amide-dihydrochloride

 

a) 3-(quinolin-3-yl-methyl-amino)-propionitrile:

1.3 mL of acrylonitrile in 4 mL ethanol are added dropwise to a well stirred solution of 3-aminomethyl-quinoline (3.0 g, 19 mmol) in 10 mL of ethanol maintained at not more than 30° C. over a period of about 0.5 h. The mixture is kept for 16 h at ambient temperature, refluxed for 1 h and the solvent is distilled off in vacuo. The residue is chromatographed over silica gel (dichloromethane:methanol 50:1). Yield: 3.0 g (75%); yellow oil;

b) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(quinolin-3-yl-methyl)-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with 3-(quinolin-3-yl-methyl-amino)-propionitrile. The crude product obtained is further reacted directly without any more purification.

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-quinolin-3-yl-methyl)-amide-dihydrochloride

The reaction was carried out starting from 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(quinolin-3-yl-methyl)-amide analogously to Example 1, step g. The product is obtained by chromatography on silica gel (dichloromethane:methanol=3:1) or by crystallisation from methanol/acetone.

Yield: 46%; melting point: >220° C.; mass: calc.: [532.65], found: [M+H]⁺ 533, [M+2H]²⁺ 267; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=7.75-7.40 (13H, m, aryl-H); 5.00 (2H, s, N—CH₂-Ph); 4.00, 2.94 (4H, 2 m, N—CH₂—CH₂—N); 3.86 (3H, s, aryl-N—CH₃); 3.41 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 9 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl -carboxylic Acid-N-(2-amidinoethyl)-N-benzyl-amide-dihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-benzyl-amide:

The synthesis is carried out starting from 4.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with 3-(benzylamino)-propionitrile analogously to Example 1, step f. The product is purified by crystallisation from ethyl acetate/diethylether.

Yield: 89%. melting point: 140-148° C.

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-benzyl-amide-dihydrochloride:

Starting from 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-benzyl-amide; Yield: 56%; melting point: >220° C.; mass: calc.: [481,60] found: [M+H]⁺ 482, [M+2H]²⁺ 242; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.38, 9.26, 9.20, 8.81 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 7.83-7.07 (12H, m, aryl-H); 4.63 (2H, s, N—CH₂-Ph); 3.67 (3H, s, aryl-N—CH₃); 3.68, 2.76 (4H, 2 m, N—CH₂—CH₂—N); 3.24 (4H, s, aryl-CH₂—CH₂).

EXAMPLE 10 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(3-pyridylmethyl)-amide-dihydrochloride

 

a) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(3-pyridylmethyl)-amide:

The synthesis is carried out analogously to step f (Example 1) by reacting 4.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid with 3-(3-pyridyl-methyl-amino)-propionitrile. The crude product obtained is further reacted directly without any more purification.

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(3-pyridylmethyl)-amide-dihydrochloride:

Starting from 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(3-pyridylmethyl)-amide the synthesis is carried out analogously to Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 7:3) and/or crystallisation from methanol/acetone with water.

Yield: 25%; melting point: 225-228° C.; mass: calc.: [482] found: [M+H]⁺ 483, [M+2H]²⁺ 242; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.41, 9.27, 9.19, 8.77 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 8.62-7.29 (11H, m, aryl-/pyridyl-H); 4.71 (2H, s, N—CH₂-Ph); 3.78 (3H, s, aryl-N—CH₃); 3.72, 2.78 (4H, 2 m, N—CH₂—CH₂); 3.29 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 11 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-iso-butyl-amide-dihydrochloride

 

a) 3-(i-Butylamino)-propionitrile

The preparation is carried out starting from 40 mmol of iso-butylamine analogously to step a (Example 8). The product obtained is used directly in the next step without any further purification. Yield: 99%;

b) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-iso-butyl-amide:

The synthesis is carried out starting from 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-(i-butylamino)-propionitrile analogously to Example 2, step b. The product is further reacted directly, without being purified.

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-iso-butyl-amide-dihydrochloride:

Starting from 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-iso-butyl-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). Yield: 43%; melting point: 204-210° C.; mass: calc.: [447] found: [M+H]⁺ 448; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.56, 9.42, 9.36, 8.96 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 8.32-7.27 (7H, m, aryl-H); 3.88, 2.79 (4H, 2 m, N—CH₂—CH₂); 3.35 (2H, m, N—CH ₂—CH); 3.32 (4H, s, aryl-CH₂—CH₂—); 1.89 (1H, m, N—CH₂—CH); 0.68 (6H, m, CH(CH ₃)₂).

EXAMPLE 12 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3-phenylpropyl)-amide-hydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3-phenylpropyl)-amide:

The synthesis is carried out starting from 6.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with 3-phenylpropylamine analogously to Example 1, step f. The product is further reacted directly, without being purified. Yield: 89%;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3-phenylpropyl)-amide-hydrochloride:

Starting from 5.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(3-phenylpropyl)-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 9:1). Yield: 56%; amorphous solid; mass: calc. [439,56], found: [M+H]⁺ 4400; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.53, 9.33 (4H, 2 s, C(═NH₂ ⁺)NH₂); 8.65 (1H, t, J=5.2 Hz, NHCO); 8.32-7.22 (12H, m, aryl-H); 3.82 (3H, s, aryl-N—CH₃); 3.41, 2.70, 1.88 (6H, 3 m, N—CH₂—CH₂—CH₂—); 3.33 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 13 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3,3-diphenylpropyl)-amide-hydrochloride

 

a) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3,3-diphenylpropyl)-amide:

The synthesis is carried out starting from 6.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with 3,3-diphenylpropylamine analogously to Example 1, step f. The product is further reacted directly, without being purified. Yield: 81%;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3,3-diphenylpropyl)-amide-hydrochloride:

Starting from 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(3,3-diphenylpropyl)-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 95:5).

Yield: 43%; melting point: 185° C.; mass: calc. [515], found: [M+H]⁺ 516 ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.63 (1H, t, J=6.2 Hz, NHCO); 8.32-7.25 (17H, m, aryl-H); 7.79 (4 h, broad, c(═NH₂ ⁺)NH₂); 4.15 (1H, t, J=6.8 Hz, —CHPh₂); 381 (3H, s, aryl-N—CH₃); 3.32 (4H, s, aryl-CH₂—CH₂—); 3.26, 2.36 (4H, 2 m, N—CH₂—CH₂—).

EXAMPLE 14 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-(N′-phenyl-piperazide)-hydrochloride

 

a) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-(N′-phenyl-piperazide):

The synthesis is carried out starting from 6.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with N-phenylpiperazine analogously to Example 1, step f. The product is further reacted directly, without any more purification. Yield: 86%;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-(N′-phenyl-piperazide)-hydrochloride:

Starting from 5.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-(N′-phenyl-piperazide) the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 95:5). Yield: 47%; amorphous solid; mass: calc.: [466,59], found: [M+H]⁺ 467; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.41, 9.22 (4H, 2 s, C(═NH₂ ⁺)NH₂); 7.89-6.79 (12H, m, aryl-H); 3.80 (3H, s, aryl-N—CH₃); 3.69, 3.19 (8H, 2 m, piperazinyl); 3.29 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 15 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-methyl-phenyl)-diazepide]-hydrochloride

 

a) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methyl-phenyl)-diazepide]:

The synthesis is carried out starting from 6.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with N-(2-methylphenyl)-diazepine analogously to Example 1, step f. The product is further reacted directly, without being purified.

¹H-NMR (250 MHz, CDCl₃): δ [ppm]=7.87-6.90 (11H, m, aryl-H); 3.96, 3.65, 3.11, 2.31, 1.94 (10H, 5 m, diazacycloheptyl); 3.62 (3H, s, N—CH₃); 3.34, 3.27 (4H, 2 m, aryl-CH₂CH₂); 2.81 (3H, s, aryl-N—CH₃).

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-methyl-phenyl)-diazepide]-hydrochloride:

Starting from 2.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methyl-phenyl)-diazepide] the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 95:5).

Yield: 48%; amorphous solid; mass: calc.: [494], found: [M+H]⁺ 495; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.42, 9.21 (4H, 2 s, C(═NH₂ ⁺)NH₂); 7.92-6.87 (11H, m, aryl-H); 3.84-1.65 (10H, 5 m, diazacycloheptane); 3.78 (3H, s, aryl-N—CH₃); 3.30 (4H, s, aryl-CH₂—CH₂—); 2.21 (3H, s, aryl-CH₃).

EXAMPLE 16 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidinobenzyl)-N-(3-phenylpropyl)-amide-dihydrochloride

 

a) (4-Cyanobenzyl)-(3-phenyl-propyl)-amine:

3-phenylpropylamine (2.5 g, 18.5 mmol), 4-cyanobenzaldehyde (2.2 g, 16.8 mmol) and 0.22 mL acetic acid in 130 mL dichloromethane are combined with 11.0 g of Na[BH(OAc)₃] (51.9 mmol) with stirring. The mixture is stirred for 1 h at RT, the dichloromethane is distilled off, taken up in ethyl acetate, combined with water and made acidic with dilute hydrochloric acid. Once the development of gas is no longer visible, the mixture is made alkaline with 4 N aqueous sodium hydroxide solution, the amine is extracted into the organic phase and the organic phase is washed with water and dried. The solvent is distilled off in vacuo and the crude product remaining (according to ¹H-NMR: 079381, 85%) is chromatographed over silica gel (dichloromethane:petroleum ether 9:1 to dichloromethane).

Yield: 3.6 g (78%).

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-cyanobenzyl)-N-(3-phenylpropyl)-amide:

The synthesis is carried out starting from 15.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with (4-cyanobenzyl)-(3-phenyl-propyl)-amine analogously to Example 1, step f. The product is further reacted directly, without being purified. Yield: >90%;

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidinobenzyl)-N-(3-phenylpropyl)-amide-dihydrochloride:

Starting from 7.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-cyanobenzyl)-N-(3-phenylpropyl)-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 95:5-9:1).

Yield: 18%; amorphous solid; mass: calc.: [571] found: [M+H]⁺ 572; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=7.88-6.70 (16H, m, aryl-H); 3.75 (5H, s, N—CH₂, aryl-N—CH₃); 3.34 (4H, s, aryl-CH₂—CH₂—); 3.50-1.68 (6H, m, N—CH₂—CH₂—CH₂).

EXAMPLE 17 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidinobenzyl)-N-(3,3-diphenylpropyl)-amide-dihydrochloride

 

a) (4-Cyanobenzyl)-(3-phenyl-propyl)-amine:

The reaction is carried out analogously to the procedure described in Example 16 (step a) starting from 18.5 mmol of 3,3-diphenylpropylamine. Yield: 65%;

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-cyanobenzyl)-N-(3,3-diphenylpropyl)-amide:

The synthesis is carried out starting from 12.1 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with (4-cyanobenzyl)-(3,3-diphenyl-propyl)-amine analogously to Example 1, step f. The product is further reacted directly, without any more purification. Yield: >90%;

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-amidinobenzyl)-N-(3,3-diphenylpropyl)-amide-dihydrochloride:

Starting from 5.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-cyanobenzyl)-N-(3,3-diphenylpropyl)-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 85:15).

Yield: 26%; amorphous solid; mass: calc.: [647], found: [M+H]⁺ 648; [M+2H]²⁺ 325; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=7.85-6.81 (21H, m, aryl-H); 3.80 (3H, s, aryl-N—CH₃); 4.16-2.13 (11H, m, aryl-CH₂—CH₂, N—CH₂, N—CH₂—CH₂—CH).

EXAMPLE 18 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-methyl-N-(3-pyridyl)-amide-hydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-methyl-N-(3-pyridyl)-amide:

The synthesis is carried out starting from 10 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with N-methyl-N-(3-pyridyl)-amine analogously to Example 2, step b. The product is further reacted directly, without any more purification.

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-methyl-N-(3-pyridyl)-amide-hydrochloride:

Starting from 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-methyl-N-(3-pyridyl)-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 4:1).

Yield: 22%; melting point: >220° C.; mass: calc.: [412], found: [M+H]⁺ 413, [2M+H]⁺ 825; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.30 (4H, s, C(═NH₂ ⁺)NH₂); 8.40-7.10 (11H, m, aryl-/pyridyl-H); 3.69 (3H, s, aryl-N—CH₃); 3.42 (3H, s, CO—N—CH₃); 3.21 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 19 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-N′,N′-dibenzylamino)ethyl]-N-phenyl-amide-dihydrochloride

 

a) N,N-dibenzyl-N′-phenyl-ethylenediamine is obtained from

N,N-dibenzylethanolamine-hydrochloride by reaction with SOCl₂ in chloroform and subsequent nucleophilic substitution with aniline.

b) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-N′,N′-dibenzylamino)ethyl]-N-phenyl-amide:

The synthesis is carried out starting from 10.4 mmol of

2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with N,N-dibenzyl-N′-phenylethylenediamine analogously to Example 2, step b. The product is obtained by crystallisation from diethylether. Yield: 92%;

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-N′,N′-dibenzylamino)ethyl]-N-phenyl-amide-dihydrochloride:

Starting from 8.3 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-[2-N′,N′-dibenzylamino)ethyl]-N-phenyl-amide the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by chromatography over silica gel (dichloromethane:methanol 95:5).

Yield: 70%; amorphous solid; mass: calc.: [620], found: [M+H]⁺ 621, [M+2H]²⁺ 311; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.34, 9.13 (4H, 2 s, C(═NH₂ ⁺)NH₂); 7.84-6.90 (22H, m, aryl-H); 4.05, 2.66 (4H, 2 t, J=6.2 Hz, N—CH₂—CH₂—N); 3.67 (3H, s, aryl-N—CH₃); 3.57 (4H, s, N-(CH ₂-Ph)₂); 3.20 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 20 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(2-naphthyl)-amide-dihydrochloride

 

a) 3-(β-Naphthyl-amino)propionitrile:

The reaction is carried out starting from 24 mmol of 2-amino-naphthaline analogously to EXAMPLE 22 (step a). The N-cyanoethyl-N-formylnaphthylamine is purified by crystallisation from ethanol (Yield: 68%; melting point: 82-84° C.). The end product is recrystallised from ethanol (Yield: 68%).

melting point: 96-98° C.;

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(2-naphthyl)-amide:

The synthesis is carried out starting from 3.8 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-(-naphthyl-amino)propionitrile analogously to Example 2, step b. The product is obtainable by crystallisation from ethyl acetate. Yield: 50%; melting point: 196-98° C.; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=7.85-7.12 (14H, m, aryl-H); 4.19, 2.89 (4H, 2 m, N—CH₂—CH₂); 3.55 (3H, s, aryl-N—CH₃); 3.08 (4H, s, aryl-CH₂—CH₂—).

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(2-naphthyl)-amide-dihydrochloride:

Starting from 1.9 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(2-naphthyl)-amide the title compound is synthesised analogously to Example 1 (step g).

Yield: 55%; amorphous solid; mass: calc.: [517], found: [M+H]⁺ 518; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=7.80-7.12 (14H, m, aryl-H); 4.39, 2.89 (4H, 2 m, N—CH₂—CH₂); 3.55 (3H, s, aryl-N—CH₃); 3.15 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 21 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-phenyl-amide-dihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-phenyl-amide:

The synthesis is carried out starting from 6.6 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-phenylamino-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate. Yield: 70%; melting point: 188-190° C.;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-phenyl-amide-dihydrochloride:

Starting from 4.1 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-phenyl-amide the reaction takes place analogously to Example 1, step g. Yield: 62%; amorphous solid; mass: calc.: [467], found: [M+H]⁺ 468; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.48, 9.30, 8,97, 8.60 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 8.00, 7.13 (12H, m, aryl-H); 2.82 (4H, 2 t, J=6.2 Hz, N—CH₂—CH₂—); 3.71 (3H, s, aryl-N—CH₃); 3.22 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 22 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(3-ethyl-phenyl)-amide-dihydrochloride

 

a) 3-(3-Ethylphenyl-amino)-propionitrile:

6.1 g (50 mmol) of 3-ethylaniline are heated in 5 mL of formic acid for 5 h to 100-120° C. and, after cooling, combined with 100 mL ethyl acetate. The mixture is then washed with dilute aqueous hydrochloric acid and with dilute aqueous sodium hydroxide solution. The organic phase is dried over magnesium sulphate and the solvent is distilled off in vacuo. The residue remaining (6.7 g of N-formyl-3-ethylaniline) is taken up in 4.6 mL of acrylonitrile, combined with powdered sodium hydroxide (0.2 g), stirred for 6 h at 80-90° C. and kept at ambient temperature for 16 h. It is diluted with 100 mL of ethyl acetate and washed with water. It is then dried over magnesium sulphate and the solvent is distilled off in vacuo. The residue (8.7 g of N-formyl-3-(3-ethylphenyl-amino)-propionitrile) is taken up in 22.5 mL of acetonitrile, combined with 22.5 mL of aqueous hydrochloric acid (5N) and stirred for 5 h at 80-90° C. It is diluted with 100 mL of ethyl acetate, poured onto water and made alkaline with sodium hydroxide. The organic phase is washed with water, dried over magnesium sulphate and the solvent is distilled off in vacuo. The pure product is obtained by chromatography over silica gel (hexane:ethyl acetate 9:1). Yield: 6.0 g (69%)

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(3-ethyl-phenyl)-amide:

The synthesis is carried out starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-(3-ethylphenyl-amino)-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate. Melting point: 122-124° C.;

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(3-ethyl-phenyl)-amide-dihydrochloride:

Starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(3-ethyl-phenyl)-amide the reaction takes place analogously to Example 1, step g.

Yield: 43%; amorphous solid; mass: calc.: [495] found: [M+H]⁺ 496, [M+2H]²⁺ 249; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.47, 9.30, 9.27, 8.87 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 7.94-6.96 (11H, m, aryl-H); 4.22, 2.82 (4H, 2 m, N—CH₂—CH₂); 3H, s, aryl-N—CH₃); 3.21 (4H, s, aryl-CH₂—CH₂—); 2.51 (2H, q, J=7.6 Hz, —Ph—CH ₂—CH₃); 1.01 (3H, t, J=7.6 Hz, —Ph—CH₂—CH ₃).

EXAMPLE 23 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(3-phenoxy-phenyl)-amide-dihydrochloride

 

a) 3-(3-Phenoxyphenyl-amino)-propionitrile:

The reaction takes place analogously to the synthesis according to Example 22, step a, starting from 3-phenoxyaniline. The product is purified by crystallisation of the hydrochloride from ethyl acetate with ethereal hydrochloric acid solution.

Yield: 72; melting point: 141-146° C. (hydrochloride)

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(3-phenoxy-phenyl)-amide:

The synthesis is carried out starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 43-(3-phenoxyphenyl-amino)-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate/diethylether. Melting point: 125-127° C.; ¹H-NMR (250 MHz, CDCl₃): δ [ppm]=7.70-6.53 (16H, m, aryl-H); 4.16, 2.82 (4H, 2 t, J=7.5 Hz, N—CH₂—CH₂); 3.55 (3H, s, aryl-N—CH₃); 3.28, 3.15 (4H, 2 m, aryl-CH₂—CH₂).

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(3-phenoxy-phenyl)-amide-dihydrochloride:

Starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(3-phenoxy-phenyl)-amide the reaction takes place analogously to Example 1, step g. Yield: 23%; amorphous solid; mass: calc.: [559] found: [M+H]⁺ 560; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=7.75-6.40 (16H, m, aryl-H); 4.30, 2.76 (4H, 2 m, N—CH₂—CH₂); 3.73 (3H, s, aryl-N—CH₃); 3.30 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 24 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(2-phenylethyl)-amide-dihydrochloride

 

a) 3-(Phenethylamino)-propionitrile

The preparation is carried out analogously to Example 8 (step a) starting from 19 mmol of phenethylamine. Yield: 79%;

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(2-phenylethyl)-amide:

The synthesis is carried out starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-(phenethylamino)-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate/diethylether. Melting point: 132-133° C.;

c) 2-[2-(4-Amidinophenyl)-ethyl]-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(2-phenylethyl)-amide-dihydrochloride

Starting from 3.8 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(2-phenylethyl)-amide the reaction takes place analogously to Example 1, step g. The purification is carried out by chromatography over silica gel (dichloromethane:methanol 4:1-7:3) and/or crystallisation from methanol/acetone with water. Yield: 52%; melting point: 185-190° C.; mass: calc.: [495] found: [M+H]⁺ 496; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.38, 9.26, 9.19, 8.77 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂);7.84-6.83 (12H, m, aryl-H); 3.84, 2.78 (4H, 2 m, N—CH₂—CH₂); s, aryl-N—CH₃); 3.46, 2.78 (4H, 2 m, N—CH₂—CH₂-Ph); 3.26 (4H, s, aryl-CH₂-CH₂)

EXAMPLE 25 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-cyclooctyl-amide-dihydrochloride

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-cyclooctyl-amide:

The synthesis is carried out starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-(cyclooctylamino)-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate. Melting point: 181-183° C.;

b) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-cyclooctyl-amide-dihydrochloride:

Starting from 3.8 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-cyclooctyl-amide the reaction takes place analogously to Example 1, step g. The purification is carried out by chromatography over silica gel (dichloromethane:methanol 4:1) and/or crystallisation from methanol/acetone with water.

Yield: 47%; melting point: 200-210° C.; mass: calc.: [501] found: [M+H]⁺ 502; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.33, 9.18, 9.13, 8.77 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 7.82-7.01 (8H, m, aryl-H); 3.88 (1H, m, N—CH-cyclooctyl); 3.74 (3H, s, aryl-N—CH₃); 3.58, 2.79 (4H, 2 m, N—CH₂—CH₂); 3.24 (4H, s, aryl-CH₂—CH₂—); 1.95-0.74 (14H, m, cyclooctyl).

EXAMPLE 26 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(4-methyl-phenyl)-amide-dihydrochloride

 

a) 3-(p-Toluyl-amino)-propionitrile:

The reaction takes place analogously to the synthesis according to Example 22, step a, starting from 4-methylaniline. The product is purified by chromatography over silica gel (hexane:ethyl acetate 9:1) and/or crystallisation from hexane.

Yield: 69%;

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-(4-methyl-phenyl)-amide:

The synthesis is carried out starting from 4.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reacting 3-(p-toluyl-amino)-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate/diethylether. Melting point: 149-152° C.;

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-(4-methyl-phenyl)-amide-dihydrochloride:

Starting from 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-(4-methyl-phenyl)-amide the reaction takes place analogously to Example 1, step g. Yield: 44%; melting point: 222-225° C.; mass: calc.: [481] found: [M+H]⁺ 482; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.41, 9.25, 9.18, 8.80 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 7.89-7.01 (11 H, m, aryl-H); 4.15, 2.78 (4H, 2 m, N—CH₂—CH₂); 3.67 (3H, s, aryl-N—CH₃); 3.18 (4H, s, aryl-CH₂—CH₂—); 2.20 (3H, s, aryl-CH ₃).

EXAMPLE 27 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-iso-propyl-amide-dihydrochloride

 

a) 3-(i-propylamino)-propionitrile:

The synthesis is carried out analogously to Example 8 (step a) starting from 40 mmol of isopropylamine. The product obtained is reacted further directly with no additional purification. Yield: 89%;

b) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-cyanoethyl)-N-iso-propyl-amide:

The synthesis is carried out starting from 3.1 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with 3-(i-propylamino)-propionitrile analogously to Example 2, step b. The product can be obtained by crystallisation from ethyl acetate/diethylether and is used directly in the next step.

c) 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-amidinoethyl)-N-iso-propyl-amide-dihydrochloride:

Starting from 3.1 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-cyanoethyl)-N-iso-propyl-amide the reaction takes place analogously to Example 1, step g. The product is purified by chromatography over silica gel (dichloromethane:methanol 4:1-7:3) and/or crystallisation from methanol/acetone with water. Yield: 59%; melting point: 195-200° C.; mass: calc.: [433] found: [M+H]⁺ 434; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.93, 9.22, 9.20, 8.80 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 7.89-7.19 (7H, m, aryl-H); 3.39 (1H, m, N—CH-Me₂); 3.65, 2.74 (4H, 2 m, N—CH₂—CH₂); 3.78 (3H, s, aryl-N—CH₃); 3.29 (4H, s, aryl-CH₂—CH₂—); 1.12 (6H, d, J=6.7 Hz, CH(CH ₃)₂).

EXAMPLE 28 Ethyl 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-(4-amidinophenyl)-propionate

 

a) ethyl 2-{2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-(4-cyanophenyl)-propionate:

The synthesis is carried out starting from 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-enzimidazol-5-yl-carboxylic acid by reaction with ethyl 2-amino-3-(4-cyanophenyl)-propionate analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromethane:methanol 50:1). Yield: 92%; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.26-7.37 (11H, m, aryl-H); 6.87 (1H, m, NHCO); 5.23 (1H, m, NH—CH—); 4.32 (2H, q, J=7.5 Hz, —O—CH₂); 3.86 (3H, s, OCH₃); 3.78 (3H, s, aryl-N—CH₃); 3.56-3.19 (6H, m, aryl-CH₂, aryl-CH₂—CH₂—); 1.31 (3H, t, J=7.5 Hz, —O—CH₂—CH ₃).

b) Ethyl 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-(4-amidinophenyl)-propionate:

Starting from 5 mmol of ethyl 2-{2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-(4-cyanophenyl)-propionate the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is purified by crystallisation from ethanol/ethyl acetate. Yield: 70%; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.27, 9.24, 9.06, 9.03 (8H, 4 s, 2 C(═NH₂ ⁺)NH₂); 8.81 (1H, m, NHCO); 8.10-6.90 (11H, m, aryl-H); 4.71 (1H, m, NH—CH); 4.08 (2H, q, J=7.5 Hz, —O—CH₂); 3.72 (3H, s, aryl-N—CH₃); 3.50-3.18 (2H, m, aryl-CH₂); 3.24 (4H, s, aryl-CH₂—CH₂—); 1.16 (3H, t, J=7.5 Hz, —O—CH₂—CH ₃).

EXAMPLE 29 Ethyl 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonyl-(methylamino)}-3-(4-amidinophenyl)-propionate-formate

 

a) Ethyl 2-{2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonyl-(methylamino)}-3-(4-cyanophenyl)-propionate:

The synthesis is carried out starting from 7 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with ethyl 2-methylamino-3-(4-cyanophenyl)-propionate analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromethane:methanol 20:1).

Yield: 61%; ¹H-NMR (250 MHz, CDCl₃): δ [ppm]=7.83-7.23 (11H, m, aryl-H); 5.47 (1H, m, N—CH); 4.38 (2H, m, —O—CH₂—); 3.69 (3H, s, aryl-N—CH₃); 3.38, 3.22 (4H, 2 m, aryl-CH₂—CH₂—CH₂); 3.12 (2H, m, aryl-CH ₂—CH—); 2.91 (3H, s, CO—N—CH₃); 1.35 (3H, t, —O—CH₂—CH ₃).

b) Ethyl 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonyl-(methylamino)}-3-(4-amidinophenyl)-propionate:

Starting from 2.8 mmol of ethyl 2-{2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonyl-(methylamino)}-3-(4-cyanophenyl)-propionate the synthesis is carried out analogously to the instructions in Example 1 (step g). The product is chromatographed over silica gel (acetonitrile:dichloromethane:formic acid:water 75:20:7.5:5). Yield: 36%; melting point: 230° C.; mass: calc.: [539]/[553], found: [M+H]⁺ 540, [M+H]⁺ 554; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.17 (1H, s, HCOOH); 8.03-6.94 (11H, m, aryl-H); 5.37 (1H, m, N—CH—); 4.35 (2H, m, —O—CH₂—); 3.90 (3H, s, aryl-N—CH₃); 3.52, 3.39 (4H, 2 m, aryl-CH₂—CH₂—); 2.87 (3H, s, CO—N—CH₃); 3.48 (2H, m, aryl-CH₂—CH—); 1.35 (3H, m, —O—CH₂—CH₃).

EXAMPLE 30 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-(4-amidinophenyl)-propionic Acid-diformate

 

After saponification of ethyl 2-{2-[2-(4-amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-2-(4-amidinobenzyl)-propionate (Example 28; 1.55 g, 2.5 mmol) with excess aqueous sodium hydroxide solution (1N) in methanol in a ratio of 1:2 at ambient temperature over 16 h, a quantity of aqueous hydrochloric acid solution (1N) corresponding to the amount of sodium hydroxide added is put in and after the solvent has been distilled off in vacuo the residue is chromatographed over silica gel (acetonitrile:dichloromethane:formic acid:water 75:20:7.5:5).

Yield: 0.55 g (36%); melting point: 165° C.; mass: calc.: [511], found: [M+H]⁺ 512; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=8.07 (2H, s, HCOOH); 7.95-7.32 (11H, m, aryl-H); 4.90 (1H, m, NH—CH); 3.69 (3H, s, aryl-N—CH₃); 3.55-3.12 (6H, m, aryl-CH₂—CH₂, aryl-CH₂).

EXAMPLE 31 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonyl-methylamino}-3-(4-amidinophenyl)-propionic Acid-formate

 

The reaction takes place analogously to the procedure described in Example 30 starting from ethyl 2-{2-[2-(4-amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonyl-(methylamino)}-3-(4-amidinophenyl)-propionate (Example 29, 1.7 mmol). The product is obtained by crystallisation from dichloromethane/methanol. Yield: >90%; melting point: 255° C.; mass: calc.: [525], found: [M+H]⁺ 526; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=10.20 (1H, s, COOH); 8.61 (1H, s, HCOOH); 8.09-6.77 (17H, m, 2 C(═NH)NH₂, aryl-H); 5.37 (1H, m, N—CH—); 3.78 (3H, s, aryl-N—CH₃); 3.33 (4H, s, aryl-CH₂—CH₂—); 2.98 (3H, s, CO—N—CH₃).

EXAMPLE 32 2-{2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N-(4-amidinobenzyl)-N-carboxymethyl-amide]-diacetate

 

The reaction takes place analogously to the procedure described in Example 30 starting from the corresponding ethyl ester (4.4 mmol).

Yield. 48%; mass: calc. [511], found: [M+H]⁺ 512, [M+2H]²⁺ 256; ¹H-NMR (250 MHz, DMSO-d6/CD₃OD): δ [ppm]=8.17-7.44 (11H, m, aryl-H); 4.65 (2H, s, N—CH₂); 4.09 (2H, s, N—CH₂—C═O); 3.82 (3H, s, aryl-N—CH₃); 3.57, 3.32 (4H, 2 m, aryl-CH₂—CH₂—); 1.86 (6H, s, CH₃—COO).

EXAMPLE 33 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-[2-(N′,N′-dimethylamino)-ethyl]-N-methyl-amide

 

1.0 g (2.8 mmol) of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[(N′,N′-dimethylaminoethyl)-N-methyl-amide] (obtainable according to Example 3, step a), NH₂OH.HCl (0.83 g) and Na₂CO₃ (0.65 g) in 50 mL methanol are refluxed for 3 h. More NH₂OH.HCl (0.4 g) and Na₂CO₃.(0.3 g) are added. After 1 h refluxing the MeOH is distilled off, the residue is mixed to a slurry in water, filtered, washed with water and dried.

Yield: 59%. ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.58 (1H, s, OH); 7.56-7.18 (7H, m, aryl-H); 5.77 (2H, s, NH₂); 3.72 (3H, s, aryl-N—CH₃); 3.18 (6H, m, aryl-CH₂—CH₂—; N—CH₂—); 2.98 (3H, s, CO—N—CH₃); 2.43 (2H, m, Me₂-N—CH ₂—); 2.16, 2.00 (6H, 2 s, N—(CH₃)₂);

EXAMPLE 34 2-{2-[2-(4-(Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-6-acetylamino-hexanoic Acid-formate

 

a) Benzyl 2-{2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-6-benzyloxycarbonyl-amino-hexanoate:

The synthesis is carried out starting from 5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with benzyl 2-amino-6-benzyloxycarbonyl-amino-hexanoate analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromethane:methanol 50:1).

Yield: 66%;

b) Benzyl 2-{2-[2-(4-(Amino-hydroximino-methyl)-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-6-benzyloxycarbonylamino-hexanoate:

Starting from 3 mmol of benzyl 2-{2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-6-benzyloxycarbonyl-amino-hexanoate the synthesis is carried out analogously to the instructions in Example 33. Potassium tert. butoxide is used as the base. The product is chromatographed over silica gel (dichloromethane:methanol 20:1). Yield: 75%;

c) 2-{2-[2-(4-(Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-6-acetylamino-hexanoic Acid-formate:

1.4 g (2 mmol) of benzyl 2-{2-[2-(4-(amino-hydroximino-methyl)-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-6-benzyloxycarbonylamino-hexanoate are taken up in 10 mL acetic acid and 2 mL acetanhydride and kept at ambient temperature for 16 h. The solvent is distilled off in vacuo and the residue remaining is hydrogenated in 40 mL methanol in the presence of 5% Pd/C (0.6 g) at normal pressure. The catalyst is filtered off, the filtrate is evaporated down and the residue is chromatographed over silica gel (acetonitrile:dichloromethane:formic acid:water 75:20:7.5:5).

Yield: 0.4 g (35%); melting point: 158° C.; mass: calc.: [492], found: [M+H]⁺ 493; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=8.27 (1H, s, HCOOH); 8.01-7.55 (7H, m, aryl-H); 4.66 (1H, m, N—CH—); 3.78 (3H, s, aryl-N—CH₃); 3.42-3.26 (4H, s, aryl-CH₂—CH₂—); 3.23 (2H, m, —N—CH₂—); 2.02-1.58 (6H, m, —N—CH₂—CH ₂—CH ₂—CH ₂—); 1.92 (3H, s, NH—CO—CH ₃).

EXAMPLE 35 2-{2-[2-(4-(Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-2-(4-acetylaminomethyl-phenyl)-propionic Acid

 

a) Methyl 2-{2-[2-(4-(Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-[4-benzyloxycarbonylaminomethyl-phenyl]-propionate:

The synthesis is carried out starting from 1.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with methyl 2-amino-3-[4-benzyloxycarbonylaminomethyl-phenyl]-propionate analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromethane:methanol 50:1). Yield: 90%;

b) Methyl 2-{2-[2-(4-(Amino-hydroximino-methyl)-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-[4-benzyloxycarbonylaminomethyl-phenyl]-propionate:

Starting from 1 mmol of methyl 2-{2-[2-(4-(cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-3-[4-benzyloxycarbonylaminomethyl-phenyl]-propionate the synthesis is carried out analogously to the instructions in Example 33. Potassium tert. butoxide is used as the base. The product is chromatographed over silica gel (dichloromethane:methanol 20:1). Yield: 74%; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.57 (1H, s, OH); 8.79 (1H, d, J=7.5 Hz, NH—CH—); 7.79 (1H, t, J=6.5 Hz, NH—CH₂—); 8.18-7.13 (16H, m, aryl-H); 5.76 (2H, s, NH₂); 5.04 (2H, s, O—CH₂—); 4.65 (1H, m, NH—CH—); 4.17 (1H, d, J=6.5 Hz, NH—CH ₂—); 3.71 (3H, s, —OCH₃); 3.66 (3H, s, aryl-N—CH₃); 3.39 (4H, m, aryl-CH₂—CH₂—); 3.18 (2H, m, aryl-CH₂—).

c) 2-{2-[2-(4-(Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino}-2-(4-acetylaminomethyl-phenyl)-propionic Acid:

Starting from 0.7 mmol of methyl 2-{2-[2-(4-(amino-hydroximino-methyl)-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carbonylamino{3-[4-benzyloxycarbonylaminomethyl-phenyl]-propionate the synthesis is carried out analogously to the instructions in Example 34 (last step).

mass: calc.: [492], found: [M+H]⁺ 493; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=10.1 (3H, broad, C(═NH)NH₂); 8.89 (1H, d, J=7.6 Hz, NH—CH); 8.40 (1H, t, J=5.8 Hz, NH—CH₂); 8.23-7.14 (11H, m, aryl-H); 4.69 (1H, m, CH—CH₂—); 4.24 (2H, d, J=5.8 Hz, NH—CH₂); 3.78 (3H, s, OCH₃); 3.69 (3H, s, aryl-N—CH₃); 3.29 (4H, s, aryl-CH₂—CH₂—); 3.15 (2H, m, CH—CH ₂—); 1.86 (3H, s, COCH ₃).

EXAMPLE 36 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N-(2-(N′-benzylamino)-ethyl)-N-cyclohexyl-amide]-dihydrochloride:

 

4.0 g (5.7 mmol) of 2-[2-(4-amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxyl acid-N-(2-(N′,N ′-dibenzylamino)-ethyl)-N-cyclohexyl-amide (Example 2) are hydrogenated in 100 mL methanol in the presence of 5% Pd/C at normal pressure and 40-60° C. The catalyst is filtered off, the filtrate is evaporated down and the residue is chromatographed over silica gel (dichloromethane/methanol 9:1-7:3).

Yield: 0.6 g (17%). mass: calc.: [536], found: [M+H]⁺ 537, [M+2H]²⁺ 269; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.34, 9.80 (4H, 2 s, C(═NH₂ ⁺)NH₂); 7.84-7.10 (12H, m, aryl-H); 4.14, 3.09 (4H, 2 m, N—CH₂—CH₂—N); 3.76 (3H, s, aryl-N—CH₃); 3.70 (2H, s, N—CH₂-Ph); 3.47 (1H, m, N-cyclohexyl-H); 3.26 (4H, s, aryl-CH₂—CH₂—); 1.92-0.54 (10H, m, cyclohexyl).

The following was also obtained from the same reaction mixture:

EXAMPLE 37 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N-(2-amino-ethyl)-N-cyclohexyl-amide]-dihydrochloride:

 

Yield: 0.4 g (13%); mass: calc.: [446], found: [M+H]447, [M+2H]²⁺ 224; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.56 (4H, broad, C(═NH₂ ⁺)NH₂); 7.66-6.98 (7H, m, aryl-H); 3.57 (3H, s, aryl-N—CH₃); 3.45, 2.78 (4H, 2 m, N—CH₂—CH₂—N); 3.35 (1H, m, N-cyclohexyl-H); 3.07 (4H, s, aryl-CH₂—CH₂—); 1.49 (2H, s, NH₂); 1.65-0.55 (10H, m, cyclohexyl).

EXAMPLE 38 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-phenylamino-ethyl)-amide-dihydrochloride

 

Using a procedure analogous to Example 36, starting from 2-[2-(4-amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N-(2-(N′,N′-dibenzylamino)-ethyl)-N-phenyl-amide] (Example 19), Example 38 was isolated.

Yield: 7%; mass: calc. [440], found: [M+H]⁺ 441, [M+2H]²⁺ 221; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.20-6.57 (12H, m, aryl-H); 3.78 (3H, s, aryl-N—CH₃); 3.51, 3.26 (4H, 2 m, N—CH₂—CH₂—N); 3.32 (4H, s, aryl-CH₂—CH₂—).

EXAMPLE 39 2-[2-(4-aminomethyl-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-phenylamino-ethyl)-amide-trihydrochloride

 

a) 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-phenylamino-ethyl)-amide:

The synthesis is carried out starting from 8.2 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid by reaction with N-phenylethylenediamine analogously to Example 1, step f. The product is obtained by crystallisation from ethyl acetate/diethylether and optionally recrystallised from acetonitrile. Yield: 86%; melting point: 161-163° C.; ¹H-NMR (250 MHz, CDCl₃): δ [ppm]=8.24-6-67 (12H, m, aryl-H); 4.21 (1H, broad, NHCO); 3.79, 3.36 (4H, 2 m, N—CH₂-CH₂—N); 3.66 (3H, s, aryl-N—CH₃); 3.66, 3.21 (4H, 2 m, aryl-CH₂—CH₂—); 1.89 (1H, broad, Ph-NH).

b) 2-[2-(4-aminomethyl-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N-(2-phenylamino-ethyl)-amide]: 2.0 g (4.7 mmol) of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(2-phenylamino-ethyl)-amide are hydrogenated in 100 mL methanol in the presence of about 2.5 g methanol-moistened Raney nickel at ambient temperature under normal pressure. The catalyst is filtered off, washed with methanol and the solvent is distilled off in vacuo. The residue is chromatographed over silica gel (dichloromethane:methanol 85:1), the trihydrochloride is crystallised from ethanol/acetone with conc. hydrochloric acid.

Yield: 1.5 g (59%); melting point: >220° C.; mass: calc.: [427], found: [M+H]⁺ 428; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.51 (1H, t, J=5.5 Hz, NHCO); 8.15-6.44 (12H, m, aryl-H); 5.71 (1H, t, J=5.5 Hz, —NH-Ph); 3.68 (3H, s, aryl-N—CH₃); 3.65 (2H, s, —N—CH ₂-Ph); 3.44, 3.12 (4H, 2 m, N—CH₂—CH₂—N); 3.22, 3.16 (4H, 2 m, aryl-CH₂—CH₂—); 3.35 (2H, broad, NH₂).

EXAMPLE 40 2-[2-(4-Aminomethyl-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(3,3-diphenylpropyl)-amide-dihydrochloride:

 

Starting from 2.8 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(3,3-diphenylpropyl)-amide (Example 13, step b) the synthesis is carried out in accordance with the method according to Example 39, step b. The reaction is carried out in the presence of 8 g of ammonia at 5 bar and 60° C. The residue is chromatographed over silica gel (dichloromethane:methanol 95:5-9:1).

Yield: 23%; melting point: 140° C.; mass: calc.: [502], found: [M+H]⁺ 503; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.99 (1H, t, J=5.4 Hz, NHCO); 8.67 (3H, broad NH₃ ⁺); 8.50-7.29 (17H, m, aryl-H); 4.29, 4.15, 2.52 (5H, 3 m, N—CH₂—CH₂—CH); 4.06 (2H, s, —CH ₂—NH₂); 3.68 (3H, s, aryl-N—CH₃); 3.63, 3.39 (4H, 2 m, aryl-CH₂—CH₂).

EXAMPLE 41 2-[2-(4-Aminomethyl-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-methyl-phenyl)-diazepide]-hydrochloride

 

Starting from 2.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methyl-phenyl)-diazepide] (Example 15, step b) the synthesis is carried out in accordance with the method according to Example 39, step b. The reaction is carried out in the presence of 8 g of ammonia at 5 bar and 60° C. The residue is chromatographed over silica gel (dichloromethane:methanol 9:1).

Yield: 48%; mass: calc.: [481], found: [M+H]⁺ 482; ¹H-NMR (250 MHz, CD₃OD): δ [ppm]=8.13-7.24 (1H, m, aryl-H); 4.10 (2H, s, —CH ₂—NH₂); 3.95 (3H, s, aryl-N—CH₃); 2.63 (3H, s, aryl-CH₃); 4.06-2.49 (10H, m, diazacycloheptanyl).

EXAMPLE 42 2-[2-(4-aminomethyl-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-aminomethyl-benzyl)-N-(3-phenylpropyl)-amide-dihydrochloride:

 

Starting from 7.8 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-cyanobenzyl)-N-(3-phenylpropyl)-amide (Example 12, step b) the synthesis is carried out in accordance with the method according to Example 39, step b.

The reaction is carried out in the presence of 8 g of ammonia at 5 bar and 60° C. The residue is chromatographed over silica gel (dichloromethane:methanol 95:5-85:15).

Yield: 42%; mass: calc.: [545], found: [M+H]⁺ 546; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.76 (6H, s, 2—NH₃ ⁺); 8.15-6.93 (16H, m, aryl-H); 4.68 (2H, s, N—CH₂-Ph); 4.08, 4.02 (4H, 2 s, CH₂—NH₂); 3.96 (3H, s, aryl-N—CH₃); 3.34 (4H, s, aryl-CH₂—CH₂—); 3.16-1.64 (6H, m, N—CH₂—CH₂—CH₂—).

EXAMPLE 43 2-[2-(4-Aminomethyl-phenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(4-aminomethylbenzyl)-N-(3,3-diphenylpropyl)-amide-dihydrochloride:

 

Starting from 8.3 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(4-cyanobenzyl)-N-(3,3-diphenylpropyl)-amide (Example 17, step b) the synthesis is carried out in accordance with the method according to Example 39, step b. The reaction is carried out in the presence of 10 g of ammonia at 5 bar and 60° C. The residue is chromatographed over silica gel (dichloromethane:methanol 9:1-4:1). Yield: 36%; melting point: 140° C.; mass: calc.: [621], found: [M+H]⁺ 622, [M+2H]²⁺ 312; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=8.51 (6H, broad, —NH₃ ⁺); 7.74-7.08 (21H, m, aryl-H); 4.66 (2H, s, N—CH₂—); 4.02, 4.00 (4H, 2 s, CH₂—NH₂); 3.84 (3H, s, aryl-N—CH₃); 3.84, 3.41, 2.24 (5H, 3 m, N—CH₂—CH₂—CH).

EXAMPLE 44 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methylphenyl)-piperazide]

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-methyl-phenyl)-piperazide]:

The synthesis is carried out starting from 7.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with N-(2-methylphenyl)piperazine analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromethane:methanol 50:1). Yield: 58%;

b) 2-{2-[4-(amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methylphenyl)-piperazide]:

Starting from 5.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-methyl-phenyl)-piperazide] the synthesis is carried out analogously to the instructions in Example 33. Potassium tert. butoxide is used as the base. The product is chromatographed over silica gel (dichloromethane:methanol 20:1). mass: calc.: [496], found: [M+H]⁺ 497; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.59 (1H, s, OH); 7.66-6.90 (11H, m, aryl-H); 5.76 (2H, s, —NH₂); 3.71 (3H, s, N—CH₃); 3.67 (4H, m —CH₂—CH₂-Ph); 3.17, 2.84 (8H, 2 m, piperazinyl); 2.26 (3H, s, aryl-N—CH₃).

EXAMPLE 45 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-methylphenyl)-piperazide]

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-methyl-phenyl)-piperazide]:

The synthesis is carried out starting from 7.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with N-(3-methylphenyl)piperazine analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromethane:methanol 50: 1). Yield: 88%;

b) 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-methylphenyl)-piperazide]:

Starting from 6.4 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(3-methyl-phenyl)-piperazide] the synthesis is carried out analogously to the instructions in Example 33. Potassium tert. butoxide is used as the base. The product is chromatographed over silica gel (dichloromethane:methanol 20:1). mass: : calc.: [496], found: [M+H]⁺ 497; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.56 (1H, s, OH); 7.66-6.90 (11H, m, aryl-H); 5.76 (2H, s, NH₂); 3.72 (3H, s, N—CH₃); 3.64 (4H, m, —CH₂—CH₂-Ph); 3.17 (8H, m, piperazinyl); 2.25 (3H, s, aryl-N—CH₃).

EXAMPLE 46 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-(N′-benzyl-piperazide)

 

a) 2-[2-(4-Cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-(N′-benzyl-piperazide):

The synthesis is carried out starting from 7.5 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid chloride by reaction with N-benzylpiperazine analogously to Example 1, step f. The product is chromatographed over silica gel (dichloromnethane:methanol 50:1). Yield: 91%;

b) 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl }-1-methyl-benzimidazol-5-yl-carboxylic Acid-(N′-benzyl-piperazide):

Starting from 6.6 mmol of 2-[2-(4-cyanophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-(N′-benzyl-piperazide) the synthesis is carried out analogously to the instructions in Example 33. Potassium tert. butoxide is used as the base. The product is chromatographed over silica gel (dichloromethane:methanol 20:1).

mass: calc.: [496], found: [M+H]⁺ 497, [M+2H]²⁺ 249; ¹H-NMR (250 MHz, DMSO-d6): δ [ppm]=9.56 (1H, s, OH); 7.62-7.16 (12H, m, aryl-H); 5.76 (2H, s, NH₂); 3.70 (3H, s, N—CH₃); 3.50 (2H, s, N—CH₂-Ph); 3.39 (4H, m, —CH₂—CH₂-Ph); 3.16, 2.39 (8H, 2 m, piperazinyl).

The following compounds were also obtained analogously to the processes described hereinbefore:

EXAMPLE 47 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-methylphenyl)-piperazide] EXAMPLE 48 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-ethoxyphenyl)-piperazide] EXAMPLE 49 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N ′-(3-isopropyloxyphenyl)-piperazide] EXAMPLE 50 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(cyclopentyl)-piperazide] EXAMPLE 51 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-methylphenyl)-piperazide] EXAMPLE 52 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-pyridyl)-piperazide] EXAMPLE 53 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-methoxyphenyl)-piperazide] EXAMPLE 54 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-ethoxyphenyl)-piperazide] EXAMPLE 55 2-[2-(4-Amidinophenyl)-ethyl]-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-benzyl-piperazide] EXAMPLE 56 2-{2-[4-(Amino-methoxycarbonylimino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-phenyl-N-[3-amino-3-methoxycarbonylimino-propyl]-amide EXAMPLE 57 2-(2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N ′-(3-hydroxyphenyl)-piperazide] EXAMPLE 58 2-{2-[4-(Amino-methoxycarbonylimino-methyl)phenyl]-ethyl)}-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-phenylethyl)-N-[3-amino-3-methoxycarbonylimino-propyl]-amide EXAMPLE 59 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic acid-[N′-(2-pyridyl)-piperazide] EXAMPLE 60 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(cyclohexyl)-piperazide] EXAMPLE 61 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(cyclopentyl)-piperazide] EXAMPLE 62 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(2-ethoxy-phenyl)-piperazide] EXAMPLE 63 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-methoxy-phenyl)-piperazide] EXAMPLE 64 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-isopropyloxy-phenyl)-piperazide] EXAMPLE 65 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(3-ethoxy-phenyl)-piperazide] EXAMPLE 66 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-phenyl-N-[3-amino-3-hydroxyimino-propyl]-amide EXAMPLE 67 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl }-1-methyl-benzimidazol-5-yl-carboxylic Acid-N-(2-phenylethyl)-N-[3-amino-3-hydroxyimino-propyl]-amide EXAMPLE 68 2-{2-[4-(Amino-hydroximino-methyl)phenyl]-ethyl}-1-methyl-benzimidazol-5-yl-carboxylic Acid-[N′-(cyclohexyl)-piperazide]

General operating method for synthesising compounds of general formula (I) on the solid phase:

a) Reductive Amination:

A suspension of 0.06 mmol of the amine coupled to the trityl resin and 300 μm of a 1:1 (v/v) solution of tetramethyl orthoformate/dichloromethane is combined with 500 μl of a 0.12 M solution of the aldehydes R⁴—CHO in tetramethyl orthoformate/dichloromethane (1:1 v/v) and shaken for 2 h at ambient temperature. Then the resin is filtered off and washed twice each with 1.5 ml of dichloromethane, dimethylformamide and dichloromethane.

The resin is suspended in 300 μl dichloromethane, combined with 1200 μl of a 0.167 M solution of sodium triacetoxyborohydride in dichloromethane and shaken for 12 hat ambient temperature. The resin is filtered off and washed twice each with 1.5 ml water, dimethylformiamide/water 7:3 (v/v), dimethylformamide/water/acetic acid 90:10:5 (v/v/v), dimethylformamide/water 9:1 (v/v), dimethylformamide, dichloromethane.

b) Acylation with 4-Chloro-3-nitro-benzoylchloride:

The resin, suspended in 500 μl diisopropylethylamine solution (20% in dichloromethane), is combined with 1000 μl of a 0.2 M solution of 4-chloro-3-nitro-benzoylchloride in dichloromethane and shaken for 12 h at ambient temperature. It is then filtered off and washed 3 times with 1.5 ml dichloromethane and 1-methyl-2-pyrrolidone.

c) Nucleophilic Substitution:

The resin, suspended in 500 μl diisopropylethylamine solution in 1-methyl-2-pyrrolidone (20% v/v). is combined with 1000 μl of a 0.1 M solution of an amine R¹—NH₂ in 1-methyl-2-pyrrolidone and heated to 85° C. for 12 h. After cooling to ambient temperature the resin is filtered off and washed 3 times with 1.5 ml of 1-methyl-2-pyrrolidone and dimethylformamide.

d) Reduction of the Nitro Group:

The resin is suspended in 500 μl dimethylformamide, combined with 1000 μl 1.0 M SnCl₂ solution in dimethylformamide and shaken for 48 h at ambient temperature. Then the resin is filtered off and washed twice with 1.5 ml dimethylformamide, dioxane, methanol/NH₄OH 98:2 (v/v), aqueous methanol (80%), methanol and tetrahydrofuran.

e) Oxidative Cyclisation to Obtain the Benzimidazole:

The resin is suspended in 500 μl of tetrahydrofuran, combined with 1000 μl of 0.1M solution of an aldehyde R²—C₆H₄—CH₂CH₂—CHO solution in THF and shaken for 48 h at ambient temperature in oxygen from the air. Then the resin is filtered off and washed 5 times with 1.5 ml tetrahydrofuran, dichloromethane/methanol 95/5 and dichloromethane.

f) Cleaving the Product from the Resin:

The resin is shaken with 1000 μl of trifluoroacetic acid, 10% v/v in dichloromethane, for 1 h at ambient temperature and suction filtered. Then the resin remaining is again combined with 500 μl of trifluoroacetic acid, 10% v/v in dichloromethane, suction filtered, and the combined filtrates are evaporated down in vacuo. After the resin residue has been treated with 1000 μl of dichloromethane/methanol 95:5 the mixture is shaken for 1 h at ambient temperature and filtered off. The filtrates and the residues obtained are combined and evaporated to dryness in vacuo.

The Tables which follow list other compounds of general formula (I) synthesised according to the invention. These may be obtained both analogously to the preceding Examples 1-68 and also according to the solid phase synthesis method described above.

 

TABLE 1 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* Found^(#) Chemical name 69 n-decyl- 686 — 343 2-[2-(4-amidinophenyl)ethyl]-1-n-decyl- benzimidazol-5-yl-carboxylic acid-N-[4- (amino-methyl)-benzyl]-N-(3-methoxy- benzyl)-amide 70

632 633 317 2-[2-(4-amidinophenyl)ethyl]-1-(3-ethoxy- propyl)-benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 71

715 716 358 2-[2-(4-amidinophenyl)ethyl]-1-(3-di-n- butylaminopropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 72

721 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid-N-[4- (amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 73

656 657 329 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 74

600 601 — 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 75

650 — 326 2-[2-(4-amidinophenyl)ethyl]-1-(2-phenyl- ethyl)-benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 76

684 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2-(4- chlorophenyl)ethyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 77

650 — 326 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 78

657 658 329 2-[2-(4-amidinophenyl)ethyl]-1-[2-(1- methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid-N-[4- (amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 79

809 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1-benzyl- 4-phenyl-piperidin-4-yl)-methyl]- benzimidazol-5-yl-carboxylic acid-N-[4- (amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 80

762 763 381 2-[2-(4-amidinophenyl)ethyl]-1-{3-[4-(2- methylphenyl)-piperazin-1-yl]-propyl}- benzimidazol-5-yl-carboxylic acid-N-[4- (amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 81

673 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]-benzimidazol-5- yl-carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 82

630 631 — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid-N-[4- (amino-methyl)-benzyl]-N-(3- methoxybenzyl)-amide 83

642 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide 84

680 681 641 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-(3-methoxybenzyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 2 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* found^(#) Chemical name 85 n-decyl- 622 623 311 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-n-butyl-amide 86

568 569 276 2-[2-(4-amidinophenyl)ethyl]-1- (3-ethoxypropyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-n-butyl-amide 87

651 652 326 2-[2-(4-amidinophenyl)ethyl]-1- (3-di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-n-butyl-amide 88

657 — — 2-[2-(4-amidinophenyl)ethyl]-1- 3-(benzylcarbonylamino)- propyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-n-butyl-amide 89

592 — — 2-[2-(4-amidinophenyl)ethyl]-1- (2-cyclohexylethyl)- benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-n-butyl-amide 90

536 — — 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-n-butyl-amide 91

586 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-n-butyl-amide 92

620 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2-(4- chlorophenyl)ethyl]-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-n-butyl-amide 93

586 — — 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino-methyl)- benzyl]-N-n-butyl-amide 94

593 594 — 2-[2-(4-amidinophenyl)ethyl]-1-[2-(1- methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid-N- [4-(amino-methyl)-benzyl]-N-n-butyl- amide 95

745 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]-N- n-butyl-amide 96

698 — — 2-[2-(4-amidinophenyl)ethyl]-1-{3-[4- (2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]-N- n-butyl-amide 97

609 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid-N- [4-(amino-methyl)-benzyl]-N-n-butyl- amide 98

566 — — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid-N- [4-(amino-methyl)-benzyl]-N-n-butyl- amide 99

578 — 290 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-n-butyl-amide 100 

616 — 309 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid-N- [4-(amino-methyl)-benzyl]-N-n-butyl- amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 3 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* found^(#) Chemical name 101 n-decyl- 656 657 329 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-benzyl-amide 102

602 603 — 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 103

685 686 343 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide 104

691 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide 105

626 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 106

570 — — 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 107

620 621 — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 108

654 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide 109

620 621 — 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 110

627 628 314 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide 111

779 — 391 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 112

732 733 367 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 113

643 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide 114

600 601 — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide 115

612 613 — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-benzyl-amide 116

650 651 326 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- benzyl-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 4 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* found^(#) Chemical name 117 n-decyl- 657 658 329 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-(2-pyridyl)-amide 118

603 604 302 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 119

686 — 344 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide 120

692 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide 121

627 628 314 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 122

571 — 286 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 123

621 — 311 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 124

655 — 329 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide 125

621 — 311 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 126

628 — 315 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide 127

780 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 128

733 734 367 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 129

644 645 323 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide 130

601 — 301 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide 131

613 — 307 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-pyridyl)-amide 132

651 652 326 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- pyridyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 5 Compounds of general formula (I) according to the invention wherein the following definitions apply: —R²: —C(═NH)NH₂;

calc. found found Ex. —R¹ [M] * # Chemical name 133 n-decyl- 657 658 329 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-(3-pyridyl)-amide 134

603 604 302 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 135

686 687 344 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide 136

692 — 347 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide 137

627 — 314 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 138

571 572 286 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 139

621 — 311 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 140

655 — 629 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide 141

621 622 311 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 142

628 — 315 2-[2-(4-amidinophenyl)ethyl]-1-[2 (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide 143

780 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 144

733 — 367 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 145

644 645 323 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide 146

601 — 301 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide 147

613 614 307 2-[2-(4-amidinophenyl)ethyl]-1-(2 thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-pyridyl)-amide 148

651 — 326 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- pyridyl)-amide *[M + H]^(+;) #[M + 2H]²⁺

 

TABLE 6 Compounds of general formula (I) according to the invention wherein the following definitions apply: —R²: —C(═NH)NH₂;

calc. found found Ex. —R¹ [M] * # Chemical name 149 n-decyl- 662 663 — 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-cyclohexylmethyl-amide 150

608 — — 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 151

691 — 346 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide 152

697 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide 153

632 −4 — 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 154

576 — — 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 155

626 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 156

660 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide 157

626 — — 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 158

633 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide 159

785 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 160

662 663 — 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 161

649 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide 162

606 — — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide 163

618 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N- cyclohexylmethyl-amide 164

656 — — 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N- cyclohexylmethyl-amide *[M + H]^(+;) #[M + 2H]²⁺

 

TABLE 7 Compounds of general formula (I) according to the invention wherein the following definitions apply: —R²: —C(═NH)NH₂;

calc. found found Ex. —R¹ [M] * # Chemical name 165 n-decyl- 684 — 343 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl] N-(3-phenylpropyl)-amide 166

630 — — 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 167

714 — — 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl) benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- phenylpropyl)-amide 168

719 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- phenylpropyl)-amide 169

654 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 170

598 — — 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 171

648 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl carboxylic acid-N-[4-(amino methyl)-benzyl]-N-(3-phenylpropyl)- amide 172

682 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3 phenylpropyl)-amide 173

648 — — 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 174

655 — 328 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- phenylpropyl)-amide 175

807 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1 benzyl-4-phenyl-piperidine-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 176

760 — — 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 177

671 — 336 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- phenylpropyl)-amide 178

628 — — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- phenylpropyl)-amide 179

640 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3-phenylpropyl)- amide 180

678 — — 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- phenylpropyl)-amide *[M + H]⁺; #[M + 2H]²⁺

 

TABLE 8 Compounds of general formula (I) according to the invention wherein the following definitions apply: —R²: —C(═NH)NH₂;

calc found found Ex. —R¹ [M] * # Chemical name 181 n-decyl- 690 691 — 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-(4-chlorbenzyl)-amide 182

636 637 319 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 183

719 720 360 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4 chlorbenzyl)-amide 184

726 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4- chlorbenzyl)-amide 185

644 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 186

604 605 — 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 187

654 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 188

688 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4- chlorbenzyl)-amide 189

654 — — 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 190

661 662 331 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4- chlorbenzyl)-amide 191

766 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 192

766 — 384 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 193

677 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4- chlorbenzyl)-amide 194

634 635 — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4- chlorbenzyl)-amide 195

646 647 — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(4-chlorbenzyl)- amide 196

684 685 — 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(4- chlorbenzyl)-amide *[M + H]⁺; #[M − 2H]²⁺

 

TABLE 9 Compounds of general formula (I) according to the invention wherein the following definitions apply: —R²: —C(═NH)NH₂;

calc. found found Ex. —R¹ [M] * # Chemical name 197 n-decyl- 724 725 363 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-(3-trifluoromethylbenzyl)-amide 198

670 671 336 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 199

753 754 377 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 200

847 — 424 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 201

753 754 377 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 202

638 639 320 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 203

688 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 204

722 — 362 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 205

688 — 345 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 206

695 — 348 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 207

847 — 424 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 208

800 801 401 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 209

711 712 356 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 210

668 669 335 2-[2-(4-amidinophenyl)ethyl]-1 (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 211

680 681 — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide 212

718 719 340 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(3- trifluoromethylbenzyl)-amide *[M + H]⁺; #[M + 2H]²⁺

 

TABLE 10 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* found^(#) Chemical name 213 n-decyl- 674 675 338 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-(2-fluorobenzyl)-amide 214

620 621 310 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 215

703 704 352 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide 216

709 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide 217

644 645 323 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 218

558 559 287 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 219

638 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 220

672 — — 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide 221

638 — — 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 222

645 — 323 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide 223

797 — 399 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 224

750 751 376 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 225

620 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide 226

618 — — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide 227

630 631 307 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2-fluorobenzyl)- amide 228

668 — — 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- fluorobenzyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 11 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* found^(#) Chemical name 229 n-decyl- 706 707 — 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-(2-naphthylmethyl)-amide 230

652 653 319 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 231

735 — 369 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide 232

741 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide 233

676 677 339 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 234

620 621 303 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 235

670 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 236

704 — 353 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide 237

670 671 328 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 238

677 678 389 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide 239

829 — 416 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 240

782 783 391 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 241

693 — 347 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide 242

650 — — 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide 243

662 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-(2- naphthylmethyl)-amide 244

700 — — 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-(2- naphthylmethyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 12 Compounds of general formula (I) according to the invention wherein the following definitions apply:

calc. Ex. —R¹ [M] found* found^(#) Chemical name 245 n-decyl- 638 639 320 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 246

584 585 293 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- [4-(methoxycarbonyl)-benzyl]-amide 247

667 668 334 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 248

673 674 337 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 249

608 609 305 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- [4-(methoxycarbonyl)-benzyl]-amide 250

552 553 277 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-[4-(methoxycarbonyl)-benzyl]- amide 251

602 603 302 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- [4-(methoxycarbonyl)-benzyl]-amide 252

636 637 319 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 253

602 603 302 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- [4-(methoxycarbonyl)-benzyl]-amide 254

609 610 305 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 255

761 — 381 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- [4-(methoxycarbonyl)-benzyl]-amide 256

714 715 358 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- [4-(methoxycarbonyl)-benzyl]-amide 257

625 626 313 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 258

582 583 292 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide 259

594 595 298 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-[4-(methoxycarbonyl)-benzyl]- amide 260

632 633 317 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-[4- (methoxycarbonyl)-benzyl]-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 13 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: −C(═NH)NH₂; −R³:

−R^(4:)

calc. found found Ex. −R¹ [M] * # Chemical name 261 n-decyl- 610 611 306 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 262

556 557 279 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-methoxybenzyl)-amide 263

639 640 320 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 264

645 — 323 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 265

580 581 291 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-methoxybenzyl)-amide 266

524 525 263 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(3-methoxybenzyl)-amide 267

574 575 288 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-methoxybenzyl)-amide 268

608 609 305 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 269

574 575 288 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-methoxybenzyl)-amide 270

581 582 291 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 271

733 734 367 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-methoxybenzyl)-amide 272

686 687 344 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-methoxybenzyl)-amide 273

597 598 299 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 274

554 555 278 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide 275

566 567 284 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(3-methoxybenzyl)-amide 276

604 605 303 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- methoxybenzyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁻

 

TABLE 14 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: −C(═NH)NH₂; −R^(3:)

−R^(4:) n-butyl calc. found found Ex. −R¹ [M] * # Chemical name 277 n-decyl- 546 — 274 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-n-butyl- amide 278

492 — 247 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N n-butyl-amide 279

575 — 288 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-n-butyl-amide 280

581 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-n-butyl-amide 281

516 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N n-butyl-amide 282

460 461 231 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-n-butyl-amide 283

510 — 256 2-[2-(4-amidinophenyl)ethyl)-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- n-butyl-amide 284

545 — 272 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-n-butyl-amide 285

510 — 255 2-[2-(4-amidinophenyl)ethyl)-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- n-butyl-amide 286

517 — 259 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-n-butyl-amide 287

669 — 335 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- n-butyl-amide 288

622 — 312 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- n-butyl-amide 289

533 — 268 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-n-butyl-amide 290

490 491 246 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-n-butyl-amide 291

502 — 252 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- ylcarboxylic acid-N-(2-aminoethyl)- N-n-butyl-amide 292

540 — 271 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N(2-aminoethyl)-N-n-butyl-amide * [M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 15 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R³:

−R⁴:

calc. found found Ex. −R¹ [M] * # Chemical name 293 n-decyl- 580 581 291 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-benzyl- amide 294

526 527 264 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- benzyl-amide 295

609 610 305 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-benzyl-amide 296

615 — 308 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylie acid- N-(2-aminoethyl)-N-benzyl-amide 297

550 551 276 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- benzyl-amide 298

494 495 248 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-benzyl-amide 299

544 545 273 2-[2-(4-amidinopheny1)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- benzyl-amide 300

578 579 290 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-benzyl-amide 301

544 545 273 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- benzyl-amide 302

551 552 276 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-benzyl-amide 303

703 — 352 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- benzyl-amide 304

656 657 329 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- benzyl-amide 305

567 568 284 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-benzyl-amide 306

524 525 263 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-benzyl-amide 307

536 537 269 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-benzyl-amide 308

574 575 288 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-benzyl-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 16 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R^(3:)

−R^(4:)

calc. found found Ex. −R¹ [M] * # Chemical name 309 n-decyl- 581 582 291 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(2- pyridyl)-amide 310

527 528 264 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N (2-pyridyl)-amide 311

610 611 306 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide 312

616 617 309 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide 313

551 552 276 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-pyridyl)-amide 314

495 496 248 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(2-pyridyl)-amide 315

545 546 273 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-pyridyl)-amide 316

579 580 291 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide 317

545 546 273 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-pyridyl)-amide 318

552 553 277 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide 319

704 — 353 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-pyridyl)-amide 320

657 658 329 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-pyridyl)-amide 321

568 569 285 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide 322

525 526 263 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide 323

537 538 269 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(2-pyridyl)-amide 324

575 576 288 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2-pyridyl)- amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 17 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R^(3:)

−R⁴:

calc. found found Ex. −R¹ [M] * # Chemical name 325 n-decyl- 581 582 291 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(3- pyridyl)-amide 326

527 528 264 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-pyridyl)-amide 327

610 611 306 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide 328

616 617 309 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl] benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide 329

551 552 276 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-pyridyl)-amide 330

495 496 248 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(3-pyridyl)-amide 331

545 546 273 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-pyridyl)-amide 332

579 580 291 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide 333

545 546 273 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-pyridyl)-amide 334

552 553 277 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide 335

704 — 353 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N (3-pyridyl)-amide 336

657 658 329 2-[2-(4-amidinophenyl)ethyl]-1- {3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-pyridyl)-amide 337

568 569 285 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide 338

525 526 263 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide 339

537 538 269 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(3-pyridyl)-amide 340

575 576 288 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3-pyridyl)- amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 18 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R³:

−R^(4:)

calc. found found Ex. −R¹ [M] * # Chemical name 341 n-decyl- 586 587 294 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 342

532 533 267 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 343

615 616 308 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide 344

621 622 311 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide 345

556 557 279 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 346

500 501 251 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-cyclohexylmethyl-amide 347

550 551 276 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 348

584 585 293 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide 349

550 551 276 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 350

557 558 279 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5 -yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide 351

708 — 355 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 352

662 663 332 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- cyclohexylmethyl-amide 353

573 574 287 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide 354

530 531 266 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide 355

542 543 272 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-cyclohexylmethyl-amide 356

580 581 291 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N- cyclohexylmethyl-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 19 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂;

calc. found found Ex. −R¹ [M] * # Chemical name 357 n-decyl 608 — 305 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 358

554 — 278 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-phenylpropyl)-amide 359

637 — 319 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 360

643 — 322 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 361

578 — 290 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzirnidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-phenylpropyl)-amide 362

522 — 262 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(3-phenylpropyl)-amide 363

572 — 287 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-arninoethyl)-N- (3-phenylpropyl)-amide 364

606 607 304 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 365

572 — 287 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-phenylpropyl)-amide 366

579 — 290 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methyl-pyrrolidin-2-yl)-ethy1]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 367

731 — 366 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-phenylpropyl)-amide 368

643 644 323 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-phenylpropyl)-amide 369

595 — 298 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 370

552 553 277 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide 371

564 — 283 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(3-phenylpropyl)-amide 372

602 — 302 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- phenylpropyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 20 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂;

calc. found found Ex. −R¹ [M] * # Chemical name 373 n-decyl 615 616 308 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(4 chlorbenzyl)-amide 374

560 561 281 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyi)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (4-chlorbenzyl)-amide 375

643 644 323 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide 376

649 650 326 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide 377

584 585 293 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5 -yl- carboxylic acid-N-(2-aminoethyl)-N- (4-chlorbenzyl)-amide 378

528 529 265 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(4-chlorbenzyl)-amide 379

578 579 290 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (4-chlorbenzyl)-amide 380

613 — 307 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide 381

578 579 290 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (4-chlorbenzyl)-amide 382

585 586 294 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide 383

737 738 370 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl carboxylic acid-N-(2-aminoethyl)-N- (4-chlorbenzyl)-amide 384

690 691 346 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl} -benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (4-chlorbenzyl)-amide 385

601 602 302 2-[2-(4-amidinophenyl)ethyl]-1-[3 (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide 386

558 559 280 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide 387

570 571 286 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(4-chlorbenzyl)-amide 388

608 609 305 2-[2-(4-amidinophenyl)ethyl]-1-(1 ,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(4-chlorbenzyl)- amide *[M + H]³⁰; ^(#)[M + 2H]²⁺

 

TABLE 21 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂;

calc. found found Ex. −R¹ [M] * # Chemical name 389 n-decyl- 648 649 325 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 390

594 595 298 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-trifluoromethylbenzyl)-amide 391

677 678 339 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 392

683 684 342 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 393

618 619 310 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-trifluoromethylbenzyl)-amide 394

562 563 282 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxyiic acid-N-(2-aminoethyl)- N-(3-trifluoromethylbenzyl)-amide 395

612 613 307 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-trifluoromethylbenzyl)-amide 396

646 647 324 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 397

612 613 307 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyi)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-trifluoromethylbenzyl)-amide 398

619 620 310 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methyipyrrolidin-2-yl)-ethyl]- benzimidazoi-5-yi-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 399

771 772 386 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-trifluoromethylbenzyl)-amide 400

724 725 363 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (3-trifluoromethylbenzyl)-amide 401

635 636 318 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 402

592 593 297 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide 403

604 605 303 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl- N-(3-trifluoromethylbenzyl)-amide 404

642 643 322 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(3- trifluoromethylbenzyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 22 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R³:

−R^(4:)

calc. found found Ex. −R¹ [M] * # Chemical name 405 n-decyl- 598 599 300 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 406

544 545 273 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-fluorobenzyl)-amide 407

627 628 314 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 408

633 634 317 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 409

568 569 285 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-fluorobenzyl)-amide 410

512 513 257 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(2-fluorobenzyl)-amide 411

562 563 282 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-fluorobenzyl)-amide 412

596 597 299 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 413

562 563 282 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-fluorobenzyl)-amide 414

569 570 285 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 415

721 722 361 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-fluorobenzyl)-amide 416

674 675 338 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-fluorobenzyl)-amide 417

585 586 293 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 418

542 543 272 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide 419

554 555 278 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(2-fluorobenzyl)-amide 420

592 593 297 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- fluorobenzyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 23 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R³:

−R^(4:)

calc. found found Ex. −R¹ [M] * # Chemical name 421 n-decyl- 630 631 316 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 422

576 577 289 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxyiic acid-N-(2-aminoethyl)-N- (2-naphthylmethyl)-amide 423

659 660 330 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 424

665 666 333 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 425

600 601 301 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-naphthylmethyl)-amide 426

544 545 273 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(2-naphthylmethyl)-amide 427

594 595 298 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-naphthylmethyl)-amide 428

628 629 315 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 429

594 595 298 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-naphthylmethyl)-amide 430

601 602 301 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 431

753 — 378 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-naphthylmethyl)-amide 432

706 707 354 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-(2-aminoethyl)-N- (2-naphthylmethyl)-amide 433

617 618 309 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 434

574 575 288 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide 435

586 — 294 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-(2-aminoethyl)- N-(2-naphthylmethyl)-amide 436

624 625 313 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-(2-aminoethyl)-N-(2- naphthylmethyl)-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

TABLE 24 Compounds of general formula (I) according to the invention wherein the following definitions apply: −R²: —C(═NH)NH₂; −R³:

−R⁴:

calc. found found Ex. −R¹ [M] * # Chemical name 437 n-decyl- 714 715 358 2-[2-(4-amidinophenyl)ethyl]-1-n- decyl-benzimidazol-5-yl-carboxylic acid-N-[4-(amino-methyl)-benzyl]- N-[4-(methoxycarbonyl)-benzyl]- amide 438

660 661 331 2-[2-(4-amidinophenyl)ethyl]-1-(3- ethoxypropyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 439

743 744 373 2-[2-(4-amidinophenyl)ethyl]-1-(3- di-n-butylaminopropyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 440

749 — — 2-[2-(4-amidinophenyl)ethyl]-1-[3- (benzylcarbonylamino)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 441

684 — 343 2-[2-(4-amidinophenyl)ethyl]-1-(2- cyclohexylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 442

628 629 315 2-[2-(4-amidinophenyl)ethyl]-1- cyclopropylmethyl-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 443

678 — 340 2-[2-(4-amidinophenyl)ethyl]-1-(2- phenylethyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 444

712 713 357 2-[2-(4-amidinophenyl)ethyl]-1-[2- (4-chlorophenyl)ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 445

678 — 340 2-[2-(4-amidinophenyl)ethyl]-1-(4- methylbenzyl)-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 446

685 — 343 2-[2-(4-amidinophenyl)ethyl]-1-[2- (1-methylpyrrolidin-2-yl)-ethyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 447

837 — — 2-[2-(4-amidinophenyl)ethyl]-1-[(1- benzyl-4-phenyl-piperidin-4-yl)- methyl]-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-bcnzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 448

790 791 396 2-[2-(4-amidinophenyl)ethyl]-1-{3- [4-(2-methylphenyl)-piperazin-1-yl]- propyl}-benzimidazol-5-yl- carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 449

701 702 351 2-[2-(4-amidinophenyl)ethyl]-1-[3- (morpholin-4-yl)-propyl]- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 450

658 659 330 2-[2-(4-amidinophenyl)ethyl]-1- (tetrahydrofuran-2-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 451

670 — — 2-[2-(4-amidinophenyl)ethyl]-1-(2- thiophenyl-methyl)-benzimidazol-5- yl-carboxylic acid-N-[4-(amino- methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide 452

708 709 347 2-[2-(4-amidinophenyl)ethyl]-1-(1,3- benzodioxol-5-yl-methyl)- benzimidazol-5-yl-carboxylic acid- N-[4-(amino-methyl)-benzyl]-N-[4- (methoxycarbonyl)-benzyl]-amide *[M + H]⁺; ^(#)[M + 2H]²⁺

 

The mass spectrometry data listed above were determined by MS-ESI (Electrospray Ionisation).

The compounds according to the invention are characterised by their tryptase-inhibiting activity. This ability to inhibit tryptase was investigated using the test described below.

The measurement is carried out in Tris HCl buffer (100 mM), which additionally contains calcium (5 mM) and heparin (100 mg/ml), at pH 7.4. The standard used is rh beta tryptase which may be obtained commercially from Promega, for example. The substrate used is N-p-tosyl-Gly-Pro-Lys-para-nitroaniline in a concentration of 0.6 mM. The substrate is digested with tryptase to form p-nitroaniline which can be measured at 405 nm. Usually, an incubation period of 5 minutes and an incubation temperature of 37° C. are chosen. The enzyme activity used is 0.91 U/ml. The measurements are carried out in an Autoanalyser (Cobas Bio) made by Hofmann LaRoche. The potential inhibitory substances are used in concentrations of 10 μM in the screening, the inhibition of the tryptase being given in percent. The IC₅₀ is determined at over 70% inhibition (concentration at which 50% of the enzyme activity is inhibited). After 5 minutes' pre-incubation of the potential inhibitory substances, the substrate is added to start the reaction, the formation of p-nitroaniline being taken as a measurement of the enzyme activity after 5 minutes, after testing the linearity.

The data obtained after the above test has been carried out (% inhibition) are assembled in Table 25 for the compounds according to the invention. The IC₅₀ values obtained for the compounds according to the invention can be found in Table 26.

TABLE 25 % Inhibition % Inhibition Example (10 μM) Example (10 μM)  70 63 124 55  71 58 125 63  72 69 128 51  74 66 129 63  75 60 130 77  76 58 134 69  80 53 135 64  81 69 136 74  82 61 137 52  86 72 138 72  87 59 139 76  88 70 140 63  90 67 144 54  91 62 145 73  93 56 146 65  96 55 147 51  97 56 150 60  98 67 152 65  99 58 154 63 100 67 155 57 103 60 161 56 104 74 162 60 106 58 166 57 107 65 167 52 113 56 168 66 114 58 169 52 118 71 170 57 119 57 173 51 120 74 177 68 121 52 178 51 122 70 182 67 123 60 183 56 184 72 284 55 186 60 288 65 187 63 290 70 193 59 291 75 194 61 294 69 198 63 295 55 200 69 296 51 202 58 298 57 203 53 304 51 209 61 306 62 210 59 307 57 214 54 310 70 216 65 312 55 219 51 314 61 225 58 322 51 226 64 323 59 230 61 326 51 231 54 330 54 232 58 342 75 233 53 346 51 235 52 352 51 237 52 354 58 241 69 355 51 242 63 358 77 262 58 359 59 266 61 362 74 274 57 369 57 278 83 370 53 279 60 371 55 280 59 374 62 282 65 375 58 283 59 378 52 384 59 386 55 387 55 390 60 394 52 400 52 402 51 406 54 422 58 438 59 440 64 442 59 443 52 444 53 445 52 450 72

 

Table 26 contains the IC₅₀ binding values obtained for the compounds according to the invention. These were measured as described above.

TABLE 26 IC₅₀ Example [μM]  1 0.887  2 0.153  3 0.66  4 0.081  5 0.245  6 0.571  7 0.67  8 0.201  9 0.14 10 0.316 11 0.086 12 0.479 15 0.098 16 0.1545 17 0.1069 18 0.312 19 0.032 20 0.31 21 0.051 22 0.056 23 0.049 24 0.016 25 0.055 26 0.168 27 0.153 29 0.158 36 0.067 37 0.068 38 0.113 40 0.192 41 0.1725 42 0.836 43 0.319 47 0.118 48 0.147 49 0.152 50 0.176 51 0.231 52 0.231 53 0.241 54 0.305 55 0.346 70 0.422 86 0.135 102  0.369 107  0.344 118  0.304 122  0.515 134  0.231 138  0.431 150  0.292 166  0.274 198  0.458 202  0.822 214  0.335 230  0.153 234  0.76 262  0.284 266  0.641 278  0.251 294  0.35 310  0.253 314  0.771 326  0.288 330  0.503 342  0.275 358  0.169 390  0.402 406  0.392 410  0.626 422  0.364

 

The tryptase inhibitors according to the invention may be administered orally, transdermally, by inhalation or parenterally. The compounds according to the invention, meaning compounds of the formulas (I) and (II), may be incorporated, as active ingredients of formula (I) or as prodrugs of the formula (II), into otherwise conventional pharmaceutical preparations, for example in compositions which consist essentially of an inert pharmaceutical carrier and an effective dose of the active substance, such as for example tablets, coated tablets, capsules, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems etc. An effective dose of the compounds according to the invention, whether of the formula (I) or (II),is between 1 and 100, preferably between 1 and 50, most preferably between 5-30 mg/dose for oral adminstration, and between 0.001 and 50, preferably between 0.1 and 10 mg/dose for intravenous or intramuscular administration. For inhalation, according to the invention, solution containing 0.01 to 1.0, preferably 0.1 to 0.5% active substance are suitable. For administration by inhalation the use of powders is preferred. It is also possible to use the compounds according to the invention as a solution for infusion, preferably in a physiological saline or nutrient saline solution.

The compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances. Suitable preparations include for example tablets, capsules, suppositories, solutions, elixirs, emulsions or dispersible powders.

Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.

Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

Solutions for injection are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.

Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.

Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.

A therapeutically effective daily dose is between 1 and 800 mg, preferably 10-300 mg per adult.

The Examples which follow illustrate the present invention without restricting its scope:

Examples of Pharmaceutical Formulations

A) Tablets per tablet active substance 100 mg lactose 140 mg corn starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg 500 mg

 

The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

B) Tablets per tablet active substance 80 mg corn starch 190 mg lactose 55 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400 mg

 

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

C) Coated tablets per coated tablet Active substance 5 mg Corn starch 41.5 mg Lactose 30 mg Polyvinylpyrrolidone 3 mg Magnesium stearate 0.5 mg 80 mg

 

The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine . The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.

D) Capsules per capsule Active substance 50 mg Corn starch 268.5 mg Magnesium stearate 1.5 mg 320 mg

 

The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.

E) Ampoule solution active substance 50 mg sodium chloride 50 mg water for inj. 5 ml

 

The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

F) Suppositories Active substance 50 mg Solid fat 1650 mg 1700 mg

 

The hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds. 

What is claimed is:
 1. A method for treating an inflammatory or allergic disease, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of the formula (I)

  wherein: R¹ denotes C₁-C₁₀-alkyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkoxy, phenoxy, hydroxyphenoxy, C₁-C₄-alkoxy-phenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO-benzyl, or phenyl-C₁-C₄-alkyl, wherein the phenyl ring may optionally be mono-, di- or tri- substituted by one or more of the groups C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a single bond or via a C₁-C₄-alkylene bridge, which heterocyclic group contains one, two or three heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, optionally by C₁-C₄-alkyl substituted phenyl or optionally by C₁-C₄-alkyl substituted benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ and R⁴ which may be identical or different, denote hydrogen, C₁-C₆-alkyl, which may be mono- or disubstituted by one or more of the groups COOH, COO—C₁-C₄-alkyl, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may optionally be mono-, di- or tri-substituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH, COO—C₁-C₄-alkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked directly or via a C₁-C₄-alkylene bridge, which heterocyclic group contains one, two, three or four heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or R³ and R⁴ together with the nitrogen atom form a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group, which heterocyclic group optionally contains one or two further heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be substituted by one or more of the groups C₁-C₄-alkyl, C_(5-C) ₆-cycloalkyl, benzyl, which may optionally be substituted by C₁-C₄-alkyl, pyridyl or phenyl, optionally substituted by C₁-C₄-alkyl, C₁-C₄-alkoxy or hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 2. A method for treating bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, allergic otitis, allergic gastro-intestinal disorders, Crohn's disease, ulcerative colitis, anaphylactic shock, septic shock, shock lung (ARDS) or arthritis, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of the formula (I)

  wherein: R¹ denotes C₁-C₁₀-alkyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkoxy, phenoxy, hydroxyphenoxy, C₁-C₄alkoxy-phenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO-benzyl, or phenyl-C₁-C₄-alkyl, wherein the phenyl ring may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a single bond or via a C₁-C₄-alkylene bridge, which heterocyclic group contains one, two or three heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, optionally by C₁-C₄-alkyl substituted phenyl or optionally by C₁-C₄-alkyl substituted benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ and R⁴ which may be identical or different, denote hydrogen, C₁-C₆-alkyl, which may be mono- or disubstituted by one or more of the groups COOH, COO—C₁-C₄-alkyl, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may optionally be mono-, di- or tri-substituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH, COO—C₁-C₄-alkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked directly or via a C₁-C₄-alkylene bridge, which heterocyclic group contains one, two, three or four heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or R³ and R⁴ together with the nitrogen atom form a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group, which heterocyclic group optionally contains one or two further heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be substituted by one or more of the groups C₁-C₄-alkyl, C₅-C₆-cycloalkyl, benzyl, which may optionally be substituted by C₁C₄-alkyl, pyridyl or phenyl, optionally substituted by C₁-C₄-alkyl, C₁-C₄-alkoxy or hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 3. A compound of the formula (I)

  wherein: R¹ denotes C₁-C₁₀-alkyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkoxy, phenoxy-, C₁-C₄-alkoxy-phenoxy, hydroxyphenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO-benzyl, or phenyl-C₁-C₄-alkyl, wherein the phenyl ring may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a single bond or via a C₁-C₄-alkylene bridge, which heterocyclic group contains one, two or three heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, optionally by C₁-C₄-alkyl substituted phenyl or optionally by C₁-C₄-alkyl substituted benzyl, or to which a benzene ring may optionally be fused via two adjacent carbon atoms; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ denotes C₁-C₆-alkyl, which is mono- or disubstituted by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or benzyl, wherein the phenyl ring is mono- or disubstituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or phenyl-C₂-C₄-alkyl, wherein the C₂-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may optionally be mono- or di-substituted, directly or via a C₁-C₄-alkylene bridge, by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂—NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or a 5 or 6 membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which heterocyclic group contains one, two or three heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl; R⁴ denotes hydrogen, C₁-C₆-alkyl, which may be mono- or disubstituted by one or more of the groups COOH, COO—C₁-C₄-alkyl or C₃-C₆-cycloalkyl, or phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl and wherein the phenyl ring may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which heterocyclic group contains one heteroatom selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono-, di- or tri-substituted by one or more of the groups C₁-C₄-alkyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or R³ and R⁴ together with the nitrogen atom form a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group, which heterocyclic group optionally contains one or two further heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and may optionally be substituted by one or more of the groups C₁-C₄-alkyl, benzyl, which is optionally C₁-C₄-alkyl-substituted, C₅-C₆-cycloalkyl, pyridyl or phenyl, which optionally bears a group selected from the group consisting of C₁-C₄-alkyl, C₁-C₄-alkoxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 4. A compound of the formula (I) according to claim 3, wherein: R¹ denotes unsubstituted C₁-C₁₀-alkyl, or may be mono- or disubstituted by C₁-C₄-alkoxy, phenoxy, C₁-C₄-alkoxy-phenoxy, hydroxyphenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO—benzyl substituted C₁-C₄-alkyl, or phenyl-C₁-C₃-alkyl, wherein the phenyl ring may optionally be mono- or disubstituted by C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁C₄-alkyl, or a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₃-alkylene bridge, which heterocyclic group contains one or two heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur and may optionally be mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl- or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ denotes C₁-C₆-alkyl, which is mono- or disubstituted by one or more of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or benzyl, wherein the phenyl ring is substituted directly or via a C₁-C₄-alkylene bridge by one of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₄-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or phenyl-C₂-C₄-alkyl, wherein the C₂-C₄-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₄-alkyl and wherein the phenyl ring may be substituted directly or via a C₁-C₄-alkylene bridge by one of the groups —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —C(═NH)NH₂ or —NH—C(═NH)NH₂, or a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which heterocyclic group contains one or two heteroatoms selected from the group consisting of oxygen and nitrogen and may optionally be mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl or benzyl; R⁴ denotes hydrogen, C₁-C₄-alkyl, which may be substituted by one of the groups COOH, COO—C₁-C₄-alkyl or C₃-C₆-cycloalkyl, or phenyl-C₁-C₄-alkyl, wherein the C₁-C₄-alkylene bridge may optionally be substituted by phenyl and wherein the phenyl ring may optionally be mono- or disubstituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono- or disubstituted by one or more of the groups C₁-C₄-alkyl, C₁-C₄-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or a 5-, 6- or 7-membered, saturated or unsaturated heterocyclic group linked via a C₁-C₄-alkylene bridge, which heterocyclic group contains one heteroatom selected from the group consisting of oxygen, nitrogen and sulphur and which may optionally be mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl or benzyl or to which a benzene ring may optionally be fused via two adjacent carbon atoms, or R³ and R⁴ together with the nitrogen atom form a 6- or 7-membered, saturated or unsaturated heterocyclic group, which contains one or two further heteroatoms selected from the group consisting of oxygen and nitrogen and which may optionally be substituted by one or more of the groups methyl, ethyl, propyl, benzyl, cyclopentyl, cyclohexyl, pyridyl or phenyl, which optionally carries a group selected from the group consisting of methyl, methoxy, ethoxy, propyloxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 5. A compound of the formula (I) according to claim 3, wherein: R¹ denotes unsubstituted C₁-C₁₀-alkyl, or by C₁-C₄-alkoxy, phenoxy, C₁-C₄-alkoxy-phenoxy, hydroxyphenoxy, C₃-C₆-cycloalkyl, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO—(C₁-C₄-alkyl), —CO—NH₂, —CO—NH—(C₁-C₄-alkyl) or —NH—CO—benzyl substituted C₁-C₄-alkyl, or phenyl-C₁-C₃-alkyl, wherein the phenyl ring may optionally be mono- or disubstituted by C₁-C₄-alkyl, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₄-alkyl, or a heterocyclic group linked via a C₁-C₃-alkylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl or benzyl, selected from the group consisting of pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, pyrimidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, triazole, furan, tetrahydrofuran, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, thiophene, dihydrothiophene, thiolan, dithiolan, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, benzodioxole, benzimidazole, benzothiophene, benzofuran and indole; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ denotes C₁-C₃-alkyl, which is substituted by —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or benzyl, wherein the phenyl ring is substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —H—CO—(C₁-C₃-alkyl), —C(═NH)NH₂ or —NH—C(═NH)NH₂, or phenyl-C₂—C₃-alkyl, wherein the C₂-C₃-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₃-alkyl and wherein the phenyl ring may be substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —C(═NH)NH₂ or —NH—C(═NH)NH₂, or a heterocyclic group linked via a C₁-C₃-alkylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl or benzyl, selected from the group consisting of pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, pyrimidine, piperazine morpholine, diazepan, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, furan, tetrahydrofuran, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, oxazole and isoxazole; R⁴ denotes hydrogen, C₁-C₄-alkyl, which may be substituted by one of the groups COOH, COO—C₁-C₃-alkyl or C₃-C₆-cycloalkyl, or phenyl-C₁-C₃-alkyl, wherein the C₁-C₃-alkylene bridge may optionally be substituted by phenyl and wherein the phenyl ring may optionally be substituted by C₁-C₃-alkyl, C₁-C₃-alkoxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₃-alkyl, or C₃-C₈-cycloalkyl, naphthyl or phenyl, which may optionally be mono- or disubstituted by one or more of the groups C₁-C₃-alkyl, C₁-C₃-alkoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH or COO—C₁-C₃-alkyl, or a heterocyclic group linked via a C₁-C₃-alkylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl- or benzyl, selected from the group consisting of pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, pyrimidine, piperazine morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, triazole, furan, tetrahydrofuran, α-pyran, γ-pyran, dioxolan, tetrahydropyran, dioxane, thiophene, dihydrothiophene, thiolan, dithiolan, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, benzodioxole, benzimidazole, benzothiophene, benzofuran and indole; or R³ and R⁴ together with the nitrogen atom form a 6- or 7-membered, saturated heterocyclic group, which contains one or two further nitrogen heteroatoms and which may optionally be substituted by one or more of the groups methyl, ethyl, propyl, benzyl, cyclopentyl, cyclohexyl, pyridyl or phenyl, which optionally carries a group selected from the group consisting of methyl, methoxy, ethoxy, propyloxy and hydroxy, or a pharmaceutically acceptable salt thereof.
 6. A compound of the formula (I) according to claim 3, wherein: R¹ denotes methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl, or a methyl, ethyl or propyl group which is substituted by methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, methoxyphenoxy, —NH₂, —NH(C₁-C₄-alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO-methyl, —CO—NH₂, —CO—NH-methyl or —NH—CO-benzyl, or benzyl, which is mono- or disubstituted by methyl, ethyl, propyl, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenylethyl, which is mono- or disubstituted by methyl, ethyl, propyl, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl or benzyl, selected from the group consisting of pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, furan, tetrahydrofuran, thiophene, benzodioxole and benzimidazole; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ denotes a methyl, ethyl or propyl group which is substituted by —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl), —NH-benzyl or —C(═NH)NH₂, or benzyl, which is substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl) or —C(═NH)NH₂, or phenyl-C₂-C₃-alkyl, wherein the C₂-C₃-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₃-alkyl and wherein the phenyl ring may be substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂, or a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by methyl, ethyl, propyl, phenyl or benzyl, selected from the group consisting of pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, diazepan, furan, tetrahydrofuran, thiophene, benzodioxole and benzimidazoles; R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group which may be substituted by one of the groups COOH, COOMe, COOEt, cyclopropyl, cyclopentyl or cyclohexyl, or benzyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenylethyl, phenylpropyl, diphenylpropyl; cyclopropyl, cyclopentyl, cyclohexyl, cyclooctyl, naphthyl or phenyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by methyl, ethyl, propyl, phenyl or benzyl, selected from the group consisting of pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, furan, tetrahydrofuran, thiophene, quinoline, isoquinoline, benzodioxole and benzimidazole; or R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring which may optionally be substituted by one of the groups methyl, ethyl, propyl, cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries a group selected from the group consisting of methyl, methoxy, ethoxy, propyloxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 7. A compound of the formula (I) according to claim 3, wherein: R¹ denotes methyl, ethyl, propyl, pentyl or n-decyl, or a methyl, ethyl- or propyl group which is substituted by methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl or methoxyphenoxy, or benzyl, which is mono- or disubstituted by methyl, CF₃, COOH, COOMe or COOEt, or a tetrahydrofuran linked via a methylene bridge; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ denotes an ethyl or propyl group which is substituted by —NH₂, —NHMe, —NMe₂, —NHEt, —NEt₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂, or Benzyl which is substituted by one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)NH₂, or phenylethyl, wherein the ethylene bridge may be substituted by COOH, COOMe or COOEt and wherein the phenyl ring is optionally substituted by one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)NH₂, or phenylpropyl, diphenylpropyl or pyridylmethyl; R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group, which may be substituted by one of the groups COOH, COOMe, COOEt, cyclopropyl, cyclopentyl or cyclohexyl, or benzyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenyl-ethyl, phenylpropyl, diphenylpropyl, or cyclopentyl, cyclohexyl, cyclooctyl, naphthyl or phenyl, which may optionally be substituted by methyl, ethyl, methoxy, ethoxy, phenyloxy or CF₃, or a pyridine or quinoline linked via a methylene bridge, or R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring, which may optionally be substituted by one of the groups cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries one of the groups selected from the group consisting of methyl, methoxy, ethoxy, propyloxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 8. A compound of the formula (I) according to claim 3, wherein: R¹ denotes methyl, ethyl, propyl, pentyl, phenylethyl, phenylpropyl, cyclopropylmethyl, tetrahydrofuranylmethyl or benzyl, which is mono- or disubstituted by CF₃, COOH, COOMe or COOEt; R² denotes —C(═NH)NH₂ or —CH₂—NH₂, preferably —C(═NH)NH₂; R³ denotes an ethyl or propyl group which is substituted by —NH₂, —NHMe, —NMe₂, —NHEt, —NEt₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂, or benzyl substituted by one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)NH₂, or phenylethyl, wherein the ethylene bridge is substituted by COOH, COOMe or COOEt and wherein the phenyl ring carries one of the groups —NH₂, —CH₂—NH₂, —NMe₂, —NHMe, —NEt₂, —NHEt, —NH—CO-Me, —CH₂—NH—CO-Me or —C(═NH)NH₂, or phenylpropyl, diphenylpropyl or pyridylmethyl; R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group which may be substituted by one of the groups COOH, COOMe, COOEt or cyclohexyl, or phenyl, which may optionally be substituted by methyl, ethyl, methoxy, ethoxy, phenyloxy or CF₃, or benzyl, phenylethyl, phenylpropyl, diphenylpropyl, cyclohexyl, cyclooctyl or naphthyl, or a pyridine or quinoline linked via a methylene bridge, or R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring, which may optionally be substituted by one of the groups cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries a group selected from the group consisisting of methyl, methoxy, ethoxy, propyloxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 9. A compound of the formula (I) according to claim 3, wherein: R¹ denotes methyl; R² denotes —C(═NH)NH₂ or —CH₂—NH₂, preferably —C(═NH)NH₂; R³ denotes ethyl, substituted by —NH₂, —NMe₂, —NHphenyl, —NHbenzyl, —N(benzyl)₂, pyrrolidine, piperidine, diazepan or —C(═NH)NH₂, benzyl substituted by one of the groups —CH₂—NH₂, —NMe₂ or —C(═NH)NH₂, phenylethyl, wherein the ethylene bridge is substituted by COOH, COOMe or COOEt and wherein the phenyl ring carries one of the groups —CH₂—NH—CO-Me or —C(═NH)NH₂, diphenylpropyl or pyridylmethyl; R⁴ denotes hydrogen or a methyl or ethyl group which may optionally be substituted by one of the groups COOH or COOEt; propyl, butyl or phenyl, which may optionally be substituted by methyl, ethyl, methoxy, ethoxy, phenyloxy or CF₃; benzyl, phenylethyl, phenylpropyl, diphenylpropyl, cyclohexyl, cyclooctyl, naphthyl, pyridylmethyl or quinolinylmethyl or R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring substituted by one of the groups benzyl, cyclopentyl, cyclohexyl or phenyl, which optionally carries a group selected from the group consisting of methyl, ethoxy, propyloxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof.
 10. A compound of the formula I, according to claim 3, wherein: R¹ denotes methyl; R² denotes —C(═NH)NH₂; R³ denotes ethyl, substituted by —NH₂, —NHphenyl, —NHbenzyl, —N(benzyl)₂, pyrrolidine, piperidine, diazepan or —C(═NH)NH₂ ; benzyl substituted by —C(═NH)NH₂ , or diphenylpropyl; R⁴ denotes hydrogen, methyl, propyl, butyl, benzyl or phenyl, which may optionally be substituted by ethyl or phenyloxy; phenylethyl, cyclohexyl or cyclooctyl, or R³ and R⁴ together with the nitrogen atom form a piperazine ring which is substituted by a group selected from the group consisting of cyclopentyl, cyclohexyl, phenyl, methylphenyl, ethoxyphenyl and propoxyphenyl, or a diazepan ring substituted by methylphenyl, or a tautomer or pharmaceutically acceptable salt thereof.
 11. A compound of the formula I, according to claim 3, wherein: R¹ denotes methyl; R² denotes —C(═NH)NH₂; R³ denotes ethyl, substituted by —NH₂, —NHbenzyl, —N(benzyl)₂, pyrrolidine, piperidine, diazepan or —C(═NH)NH₂, benzyl substituted by —C(═NH)NH₂, or diphenylpropyl; R⁴ denotes hydrogen, methyl, butyl or phenyl, which may optionally be substituted by ethyl or phenyloxy; phenylethyl, cyclohexyl or cyclooctyl, or a tautomer or pharmaceutically acceptable salt thereof.
 12. A compound of the formula (II)

  wherein R¹ and R⁴ are defined as in claim 3 and R³ may have the meanings given in claim 3 or denotes C₁-C₄-alkyl , which is substituted by a group selected from the group consisting of —C(═NOH)NH₂, —C(═NCOO—C₁-C₄-alkyl)NH₂ and —C(═NCOO—C₁-C₄-alkyl-phenyl)NH₂; R⁵ denotes hydroxy, —COO—C₁-C₈-alkyl or —COO—C₁-C₄-alkyl-phenyl, whilst in the abovementioned group the phenyl ring may be substituted by C₁-C₄-alkyl or C₁-C₄-alkoxy, or a tautomer or pharmaceutically acceptable salt thereof.
 13. A compound of the formula II, according to claim 12, wherein: R¹ and R⁴ have the meanings given in claim 3; R³ has the meanings given in claim 3, or denotes C₁-C₄-alkyl, which is substituted by a group selected from the group comprising —C(═NOH)NH₂, —C(═NCOOmethyl)NH₂, —C(NCOOethyl)NH₂, —C(═NCOOpropylyl)NH₂ or —C(═NCOO-benzyl)NH₂; R⁵ denotes hydroxy, methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, or benzyloxycarbonyl; or a tautomer or pharmaceutically acceptable salt thereof.
 14. A compound of the formula (III)

  wherein the groups R¹, R³ and R⁴ have the meanings given in claim
 3. 15. A pharmaceutical composition comprising a compound of the formula I, in accordance with claim
 3. 16. A pharmaceutical composition comprising a compound of the formula II, in accordance with claim
 12. 17. A compound of the formula (I)

  wherein: R¹ denotes methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl, or a methyl, ethyl or propyl group which is substituted by methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, methoxyphenoxy, —NH₂, —NH(C₁-C₄alkyl), —N(C₁-C₄-alkyl)₂, —NH—CO-methyl, —CO—NH₂, —CO—NH-methyl or —NH—CO-benzyl, or benzyl, which is mono- or disubstituted by methyl, ethyl, propyl, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenylethyl, which is mono- or disubstituted by methyl, ethyl, propyl, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by one or more of the groups methyl, ethyl, propyl, phenyl, methylphenyl or benzyl, selected from the group consisting of pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, furan, tetrahydrofuran, thiophene, benzodioxole and benzimidazole; R² denotes —C(═NH)NH₂ or —CH₂—NH₂; R³ denotes a methyl, ethyl or propyl group which is substituted by —NH₂, —NH(C₁-C₃alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl), —NH-benzyl or —C(═NH)NH₂, or benzyl, which is substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₄-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂, —NH—CO—(C₁-C₃-alkyl) or —C(═NH)NH₂, or phenyl-C₂-C₃-alkyl, wherein the C₂-C₃-alkylene bridge may optionally be substituted by phenyl, COOH or COO—C₁-C₃-alkyl and wherein the phenyl ring may be substituted directly or via a methylene bridge by one of the groups —NH₂, —NH(C₁-C₃-alkyl), —N(C₁-C₃-alkyl)₂, —NHphenyl, —N(phenyl)₂, —NHbenzyl, —N(benzyl)₂ or —C(═NH)NH₂, or a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by methyl, ethyl, propyl, phenyl or benzyl, selected from the group consisting of pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, diazepan, furan, tetrahydrofuran, thiophene, benzodioxole and benzimidazoles; R⁴ denotes hydrogen or a methyl, ethyl, propyl or butyl group which may be substituted by one of the groups COOH, COOMe, COOEt, cyclopropyl, cyclopentyl or cyclohexyl, or benzyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or phenylethyl, phenylpropyl, diphenylpropyl; cyclopropyl, cyclopentyl, cyclohexyl, cyclooctyl, naphthyl or phenyl, which may optionally be substituted by methyl, ethyl, propyl, methoxy, ethoxy, phenyloxy, benzyloxy, CF₃, fluorine, chlorine, bromine, COOH, COOMe or COOEt, or a heterocyclic group linked via a methylene, ethylene or propylene bridge, optionally mono- or disubstituted by methyl, ethyl, propyl, phenyl or benzyl, selected from the group consisting of pyrrole, pyrrolidine, pyridine, piperidine, piperazine, morpholine, furan, tetrahydrofuran, thiophene, quinoline, isoquinoline, benzodioxole and benzimidazole; or R³ and R⁴ together with the nitrogen atom form a piperazine or diazepan ring which may optionally be substituted by one of the groups methyl, ethyl, propyl, cyclopentyl, cyclohexyl, pyridyl, benzyl or phenyl, which optionally carries a group selected from the group consisting of methyl, methoxy, ethoxy, propyloxy and hydroxy, or a tautomer or pharmaceutically acceptable salt thereof. 